Binding agents binding to epcam and / or CD137

By developing bispecific antibodies that combine EpCAM and CD137, the problem of insufficient recognition and attack ability of tumor cells in existing tumor treatment methods is solved, and efficient recognition and attack of tumor cells is achieved, and a new tumor treatment is provided. Strategy.

CN119013301APending Publication Date: 2024-11-22GENMAB AS +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033835.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-15
Filing Date
2023-03-14
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing tumor treatment methods are difficult to effectively prevent or treat tumors or cancer, especially due to the limited application of EpCAM and CD137 in tumor immunotherapy.

Method used

A binding agent is developed that contains an antigen binding region bound to EpCAM and CD137, utilizing specific HCDR and LCDR sequences to improve their binding capacity and specificity, forming bispecific antibodies to target tumor cells.

Benefits of technology

By binding the antigen-binding region of EpCAM and CD137, the recognition and attack ability of tumor cells is enhanced and the immune response is improved, providing a potential new avenue for tumor treatment and prevention.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005080860250000681
    Figure BDA0005080860250000681
  • Figure BDA0005080860250000691
    Figure BDA0005080860250000691
  • Figure BDA0005080860250000701
    Figure BDA0005080860250000701
Patent Text Reader

Abstract

The present invention provides binding agents that bind to EpCAM and CD137, which can be used to treat or prevent a tumor or cancer, or to prevent the progression of a tumor or cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to binding agents that bind to EpCAM and CD137. Such binding agents can be used to treat or prevent tumors or cancers. Background Art

[0002] Epithelial cell adhesion molecule (EpCAM) is a Ca-mediated 2+ -A transmembrane glycoprotein for homotypic cell-cell adhesion that is independent of EpCAM. EpCAM is also involved in cell signaling, migration, proliferation and differentiation. In addition, EpCAM has oncogenic potential through its ability to upregulate c-Myc, E-FABP and cyclins A & E. EpCAM can be used as a diagnostic marker for a variety of cancers. In addition, EpCAM has been shown to play a role in tumorigenesis and metastasis of cancer, and, therefore, it can also be used as a potential prognostic marker and as a potential target for immunotherapy strategies.

[0003] CD137 (4-1BB) is a member of the TNFR family and is a co-stimulatory molecule on CD8+T cells and CD4+T cells, regulatory T cells (regulatory T cell, Treg), natural killer (T) cells (Natural Killer, NK [T] cells), B cells and neutrophils. On T cells, CD137 is not constitutively expressed, but is induced when the T cell receptor (T-cellreceptor, TCR) is activated (for example, on tumor infiltrating lymphocytes [tumor infiltratinglymphocyte, TIL; Gros et al., J.Clin Invest 2014; 124 (5): 2246-59]). Stimulation by its natural ligand 4-1BBL or agonist antibodies leads to signal transduction using TRAF-2 and TRAF-1 as adapters. Early signal transduction through CD137 involves K63 polyubiquitination reaction, which ultimately leads to the activation of nuclear factor (NF)-κB and mitogen-activated protein (MAP)-kinase pathway. Signal transduction leads to increased T cell co-stimulation, proliferation, cytokine production, maturation and prolonged CD8+T cell survival. It has been shown that agonistic antibodies against CD137 promote anti-tumor control by T cells in a variety of preclinical models (Murillo et al., Clin Cancer Res 2008; 14 (21): 6895-906). Antibodies that stimulate CD137 can induce the survival and proliferation of T cells, thereby enhancing anti-tumor immune responses. Antibodies that stimulate CD137 have been disclosed in the prior art and include the human IgG4 antibody urelumab (AU 2004279877) and the human IgG2 antibody utomilumab (Fisher et al., 2012, Cancer Immunol. Immunother. 61: 1721-1733).

[0004] There is a need for materials and methods for preventing or treating tumors or cancer. Summary of the invention

[0005] In a first aspect, the present disclosure provides a binding agent comprising a first antigen binding region that binds to EpCAM and a second antigen binding region that binds to CD137.

[0006] In some embodiments, EpCAM is human EpCAM. In some embodiments, CD137 is human CD137. In some embodiments, human EpCAM comprises the sequence shown in SEQ ID NO:59. In some embodiments, human CD137 comprises the sequence shown in SEQ ID NO:62.

[0007] In some embodiments, the first antigen binding region that binds to EpCAM binds to EpCAM expressed on tumor cells.

[0008] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR3 sequence, and the HCDR3 sequence comprises the sequence shown in SEQ ID NO: 4. In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR2 sequence, and the HCDR2 sequence comprises the sequence shown in SEQ ID NO: 3. In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR1 sequence, and the HCDR1 sequence comprises the sequence shown in SEQ ID NO: 2. In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NO: 2, 3, and 4, respectively. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 65, and 66, respectively. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 3, and 66, respectively.

[0009] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR3 sequence, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO: 8. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR2 sequence, and the LCDR2 sequence comprises the sequence shown in SEQ ID NO: 7. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR1 sequence, and the LCDR1 sequence comprises the sequence shown in SEQ ID NO: 6. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences, wherein LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NO: 6, 7, and 8, respectively. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 67, 68 and 8, respectively.

[0010] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR3 sequence and a light chain variable region (VL) comprising a LCDR3 sequence, wherein the HCDR3 sequence comprises the sequence shown in SEQ ID NO:4, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO:8.

[0011] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively.

[0012] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 65 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 67, 68 and 8, respectively.

[0013] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 3 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively.

[0014] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO:1, and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO:5.

[0015] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:1.

[0016] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO:1.

[0017] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:5.

[0018] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the sequence shown in SEQ ID NO:5.

[0019] In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identity to the sequence shown in SEQ ID NO: 1, and VL comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identity to the sequence shown in SEQ ID NO: 5. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 1, and VL comprises a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 5. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 1, and VL comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 5. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 95% identity with the sequence shown in SEQ ID NO: 1, and VL comprises a sequence having at least 95% identity with the sequence shown in SEQ ID NO: 5.

[0020] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO:1, and VL comprises the sequence shown in SEQ ID NO:5.

[0021] In some embodiments, the first antigen binding region that binds to EpCAM comprises the heavy chain variable region and light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region (VH) and / or light chain variable region (VL) as shown above and / or has the EpCAM specificity of the antibody.

[0022] In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a HCDR3 sequence, and the HCDR3 sequence comprises the sequence shown in SEQ ID NO: 14. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a HCDR2 sequence, and the HCDR2 sequence comprises the sequence shown in SEQ ID NO: 13. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a HCDR1 sequence, and the HCDR1 sequence comprises the sequence shown in SEQ ID NO: 12. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NO: 12, 13, and 14, respectively. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 69, 70, and 71, respectively. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 75, 13, and 71, respectively.

[0023] In some embodiments, the second antigen-binding region that binds to CD137 comprises a light chain variable region (VL) comprising a LCDR3 sequence, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO: 18. In some embodiments, the second antigen-binding region that binds to CD137 comprises a light chain variable region (VL) comprising a LCDR2 sequence, and the LCDR2 sequence comprises the sequence shown in SEQ ID NO: 17. In some embodiments, the second antigen-binding region that binds to CD137 comprises a light chain variable region (VL) comprising a LCDR1 sequence, and the LCDR1 sequence comprises the sequence shown in SEQ ID NO: 16. In some embodiments, the second antigen-binding region that binds to CD137 comprises a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences, wherein LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NO: 16, 17, and 18, respectively. In some embodiments, the second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 72, 73 and 18, respectively.

[0024] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a HCDR3 sequence and a light chain variable region (VL) comprising a LCDR3 sequence, wherein the HCDR3 sequence comprises the sequence shown in SEQ ID NO: 14, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO: 18.

[0025] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0026] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 69, 70 and 71, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 72, 73 and 18, respectively.

[0027] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 75, 13 and 71, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0028] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 11, and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 15.

[0029] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:11.

[0030] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO:11.

[0031] In some embodiments, the second antigen binding region that binds to CD137 comprises a light chain variable region (VL), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:15.

[0032] In some embodiments, the second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising the sequence shown in SEQ ID NO:15.

[0033] In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identity to the sequence shown in SEQ ID NO: 11, and VL comprises a sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identity to the sequence shown in SEQ ID NO: 15. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 11, and VL comprises a sequence having at least 80% identity to the sequence shown in SEQ ID NO: 15. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 11, and VL comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 15. In some embodiments, the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 95% identity with the sequence shown in SEQ ID NO: 11, and VL comprises a sequence having at least 95% identity with the sequence shown in SEQ ID NO: 15.

[0034] In some embodiments, the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 11, and VL comprises the sequence shown in SEQ ID NO: 15.

[0035] In some embodiments, the second antigen binding region that binds to CD137 comprises the heavy chain variable region and light chain variable region of such an antibody: it competes for CD137 binding with an antibody comprising the heavy chain variable region and / or light chain variable region as shown above and / or has the CD137 specificity of the antibody.

[0036] In some embodiments,

[0037] a) the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising the HCDR3 sequence shown in SEQ ID NO: 4, and

[0038] b) The second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising the HCDR3 sequence shown in SEQ ID NO: 14.

[0039] In some embodiments,

[0040] a) the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 8, and

[0041] b) The second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 18.

[0042] In some embodiments,

[0043] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises the HCDR3 sequence shown in SEQ ID NO: 4, and the light chain variable region (VL) comprises the LCDR3 sequence shown in SEQ ID NO: 8, and

[0044] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising the HCDR3 sequence shown in SEQ ID NO: 14, and the light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 18.

[0045] In some embodiments,

[0046] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and

[0047] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0048] In some embodiments,

[0049] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 65 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 67, 68 and 8, respectively; and

[0050] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 69, 70 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 72, 73 and 18, respectively.

[0051] In some embodiments,

[0052] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 3 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and

[0053] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 75, 13 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0054] In some embodiments,

[0055] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 1, and the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 5; and

[0056] b) the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 11, and the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 15.

[0057] In some embodiments,

[0058] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 1, and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 5; and

[0059] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 11, and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 15.

[0060] In some embodiments,

[0061] a) the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 1, and VL comprises the sequence shown in SEQ ID NO: 5; and

[0062] b) The second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 11, and VL comprises the sequence shown in SEQ ID NO: 15.

[0063] In some embodiments, the first antigen-binding region that binds to EpCAM comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to EpCAM as shown above and / or has the EpCAM specificity of the antibody, and the second antigen-binding region that binds to CD137 comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for CD137 binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to CD137 as shown above and / or has the CD137 specificity of the antibody.

[0064] In some embodiments, the variable region comprises three complementarity determining regions (CDR1, CDR2, and CDR3) and four framework regions (FR1, FR2, FR3, and FR4).

[0065] In some embodiments, the complementarity determining regions and the framework regions are arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0066] In some embodiments, the binding agent is in the form of a full-length antibody or an antibody fragment.

[0067] In some embodiments, the binding agent is a multispecific binding agent, such as a bispecific binding agent.

[0068] In some embodiments, the binding agent is a multispecific antibody, such as a bispecific antibody.

[0069] In some embodiments, the binding agent comprises (i) a first heavy chain variable region (VH) and a first light chain variable region (VL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0070] (ii) a second heavy chain variable region (VH) and a second light chain variable region (VL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0071] In some embodiments, the binding agent comprises

[0072] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0073] ii) a polypeptide containing a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and a polypeptide containing a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0074] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0075] The first binding arm comprises

[0076] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL);

[0077] and the second binding arm comprises

[0078] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0079] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0080] The first binding arm comprises

[0081] i) a first heavy chain comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and

[0082] ii) a first light chain comprising a first light chain variable region (VL) and a first light chain constant region (CL); and the second binding arm comprises

[0083] i) a second heavy chain comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and

[0084] ii) a second light chain comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0085] In some embodiments, the first binding arm is derived from a full-length antibody. In some embodiments, the first binding arm is derived from a monoclonal antibody. In some embodiments, the first binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the second binding arm is derived from a full-length antibody. In some embodiments, the second binding arm is derived from a monoclonal antibody. In some embodiments, the second binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first and second binding arms are derived from a full-length antibody, for example, from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first and second binding arms are derived from a monoclonal antibody.

[0086] In some embodiments, the first and second heavy chain constant regions (CH) each comprise one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region, and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region, and a CH3 region.

[0087] In some embodiments, the first and second heavy chain constant regions (CH) each comprise a CH3 region, and wherein the two CH3 regions comprise an asymmetric mutation.

[0088] In some embodiments, in the first heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and in the second heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and wherein the first heavy chain and the second heavy chain are not replaced in the same position.

[0089] In some embodiments, (i) in the first heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) in the first heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0090] In some embodiments, the binding agent induces Fc-mediated effector function to a lesser extent than another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CH) comprising human IgG1 hinge, CH2, and CH3 regions.

[0091] In some embodiments, the first heavy chain constant region and the second heavy chain constant region (CH) are modified such that the antibody induces Fc-mediated effector function to a lesser extent than an identical antibody except for comprising an unmodified first heavy chain constant region and a second heavy chain constant region (CH).

[0092] In some embodiments, each of the unmodified first heavy chain constant region and the second heavy chain constant region (CH) comprises the amino acid sequence shown in SEQ ID NO:47.

[0093] In some embodiments, the Fc-mediated effector function is measured by binding to an Fcγ receptor, binding to C1q, or induction of Fc-mediated cross-linking of Fcγ receptors.

[0094] In some embodiments, the Fc-mediated effector function is measured by binding to CIq.

[0095] In some embodiments, the first heavy chain constant region and the second heavy chain constant region have been modified such that binding of C1q to the antibody is reduced compared to the wild-type antibody, preferably by at least 70%, at least 80%, at least 90%, at least 95%, at least 97% or 100%, wherein C1q binding is preferably determined by ELISA.

[0096] In some embodiments, in at least one of the first heavy chain constant region and the second heavy chain constant region (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, P331 and G236 in the human IgG1 heavy chain according to EU numbering are not L, L, D, N, P and G, respectively.

[0097] In some embodiments, in the first and second heavy chains, the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively.

[0098] In some embodiments, in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and / or in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0099] In some embodiments,

[0100] (i) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively;

[0101] (ii) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively; or

[0102] (iii) in one of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the other of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0103] In some embodiments, the positions of both the first heavy chain constant region and the second heavy chain constant region corresponding to positions L234 and L235 in the human IgG1 heavy chain according to EU numbering are F and E, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0104] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0105] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R.

[0106] In some embodiments, the constant region of the first and / or second heavy chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:47.

[0107] In some embodiments,

[0108] a) the constant region of the first heavy chain comprises the amino acid sequence shown in SEQ ID NO: 54; and

[0109] b) the constant region of the second heavy chain comprises the amino acid sequence shown in SEQ ID NO:52.

[0110] In some embodiments, the binding agent comprises a kappa (κ) light chain constant region.

[0111] In some embodiments, the binding agent comprises a lambda (λ) light chain constant region.

[0112] In some embodiments, the first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0113] In some embodiments, the second light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0114] In some embodiments,

[0115] (i) the first light chain constant region and the second light chain constant region are kappa (κ) light chain constant regions,

[0116] (ii) the first light chain constant region and the second light chain constant region are lambda (λ) light chain constant regions,

[0117] (iii) the first light chain constant region is a kappa (κ) light chain constant region, and the second light chain constant region is a lambda (λ) light chain constant region, or (iv) the first light chain constant region is a lambda (λ) light chain constant region, and the second light chain constant region is a kappa (κ) light chain constant region.

[0118] In some embodiments, the kappa (κ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:55.

[0119] In some embodiments, the lambda (λ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:56.

[0120] In some embodiments, the binding agent has an isotype selected from IgG1, IgG2, IgG3, and IgG4. In one embodiment, the isotype is selected from human IgG1, human IgG2, human IgG3, and human IgG4.

[0121] In some embodiments, the binding agent is a full length IgG1 antibody.

[0122] In some embodiments, the binding agent is an antibody of the IgG1m(f) allotype.

[0123] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0124] The first binding arm comprises

[0125] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first VH comprises a first HCDR1, HCDR2 and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2 and LCDR3 sequence, wherein the first HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the first LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively;

[0126] and the second binding arm comprises

[0127] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively;

[0128] wherein in the first CH, positions L234, L235, and G236 in the human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the second CH, positions L234, L235, and D265 in the human IgG1 heavy chain according to EU numbering are F, E, and A; and

[0129] wherein in the first CH, the amino acid in the position corresponding to F405 in human IgG1 heavy chain according to EU numbering is L, and in the second CH, the amino acid in the position corresponding to K409 in human IgG1 heavy chain according to EU numbering is R.

[0130] In some embodiments, the binding agent comprises

[0131] i) a first heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:9,

[0132] ii) a first light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 10,

[0133] iii) a second heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 19; and

[0134] iv) a second light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:20.

[0135] In some embodiments, the binding agent comprises

[0136] i) a first heavy chain comprising the amino acid sequence shown in SEQ ID NO: 9,

[0137] ii) a first light chain comprising the amino acid sequence shown in SEQ ID NO: 10,

[0138] iii) a second heavy chain comprising the amino acid sequence shown in SEQ ID NO: 19; and

[0139] iv) a second light chain comprising the amino acid sequence shown in SEQ ID NO: 20.

[0140] In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR3 sequence, and the HCDR3 sequence comprises the sequence shown in SEQ ID NO: 78. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR2 sequence, and the HCDR2 sequence comprises the sequence shown in SEQ ID NO: 77. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR1 sequence, and the HCDR1 sequence comprises the sequence shown in SEQ ID NO: 76. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 76, 77, and 78, respectively. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 82, 83, and 84, respectively. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 87, 77, and 84, respectively.

[0141] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR3 sequence, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO: 81. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR2 sequence, and the LCDR2 sequence comprises the sequence shown in SEQ ID NO: 80. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR1 sequence, and the LCDR1 sequence comprises the sequence shown in SEQ ID NO: 79. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences, wherein LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NO: 79, 80, and 81, respectively. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 85, 86 and 81, respectively.

[0142] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR3 sequence and a light chain variable region (VL) comprising a LCDR3 sequence, wherein the HCDR3 sequence comprises the sequence shown in SEQ ID NO:78, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO:81.

[0143] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 76, 77 and 78, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 79, 80 and 81, respectively.

[0144] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 82, 83 and 84, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 85, 86 and 81, respectively.

[0145] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 87, 77 and 84, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 79, 80 and 81, respectively.

[0146] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 21 (positions 1 to 116), and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 22 (positions 1 to 112).

[0147] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:21 (positions 1 to 116).

[0148] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 21 (positions 1 to 116).

[0149] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:22 (positions 1 to 112).

[0150] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 22 (positions 1 to 112).

[0151] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:21 (positions 1 to 116), and VL comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:22 (positions 1 to 112). In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 21 (positions 1 to 116), and VL comprises a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 22 (positions 1 to 112). In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 21 (positions 1 to 116), and VL comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 22 (positions 1 to 112). In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 95% identical to the sequence shown in SEQ ID NO:21 (positions 1 to 116), and VL comprises a sequence that is at least 95% identical to the sequence shown in SEQ ID NO:22 (positions 1 to 112).

[0152] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO:21 (positions 1 to 116), and VL comprises the sequence shown in SEQ ID NO:22 (positions 1 to 112).

[0153] In some embodiments, the first antigen binding region that binds to EpCAM comprises the heavy chain variable region and light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region (VH) and / or light chain variable region (VL) as shown above and / or has the EpCAM specificity of the antibody.

[0154] In some embodiments, the second antigen binding region that binds to CD137 is as shown above.

[0155] In some embodiments,

[0156] a) the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising the HCDR3 sequence shown in SEQ ID NO: 78, and

[0157] b) The second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising the HCDR3 sequence shown in SEQ ID NO: 14.

[0158] In some embodiments,

[0159] a) the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 81, and

[0160] b) The second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 18.

[0161] In some embodiments,

[0162] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises the HCDR3 sequence shown in SEQ ID NO: 78, and the light chain variable region (VL) comprises the LCDR3 sequence shown in SEQ ID NO: 81, and

[0163] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising the HCDR3 sequence shown in SEQ ID NO: 14, and the light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 18.

[0164] In some embodiments,

[0165] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 76, 77 and 78, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 79, 80 and 81, respectively; and

[0166] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0167] In some embodiments,

[0168] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 82, 83 and 84, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 85, 86 and 81, respectively; and

[0169] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 69, 70 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 72, 73 and 18, respectively.

[0170] In some embodiments,

[0171] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 87, 77 and 84, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 79, 80 and 81, respectively; and

[0172] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 75, 13 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0173] In some embodiments,

[0174] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 21 (positions 1 to 116), and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 22 (positions 1 to 112); and

[0175] b) the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 11, and the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 15.

[0176] In some embodiments,

[0177] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 21 (positions 1 to 116), and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 22 (positions 1 to 112); and

[0178] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 11, and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 15.

[0179] In some embodiments,

[0180] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 21 (positions 1 to 116), and VL comprises the sequence shown in SEQ ID NO: 22 (positions 1 to 112); and

[0181] b) The second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 11, and VL comprises the sequence shown in SEQ ID NO: 15.

[0182] In some embodiments, the first antigen-binding region that binds to EpCAM comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to EpCAM as shown above and / or has the EpCAM specificity of the antibody, and the second antigen-binding region that binds to CD137 comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for CD137 binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to CD137 as shown above and / or has the CD137 specificity of the antibody.

[0183] In some embodiments, the variable region comprises three complementarity determining regions (CDR1, CDR2, and CDR3) and four framework regions (FR1, FR2, FR3, and FR4).

[0184] In some embodiments, the complementarity determining regions and the framework regions are arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0185] In some embodiments, the binding agent is in the form of a full-length antibody or an antibody fragment.

[0186] In some embodiments, the binding agent is a multispecific binding agent, such as a bispecific binding agent.

[0187] In some embodiments, the binding agent is a multispecific antibody, such as a bispecific antibody.

[0188] In some embodiments, the binding agent comprises (i) a first heavy chain variable region (VH) and a first light chain variable region (VL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0189] (ii) a second heavy chain variable region (VH) and a second light chain variable region (VL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0190] In some embodiments, the binding agent comprises

[0191] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0192] ii) a polypeptide containing a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and a polypeptide containing a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0193] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0194] The first binding arm comprises

[0195] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL);

[0196] and the second binding arm comprises

[0197] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0198] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0199] The first binding arm comprises

[0200] i) a first heavy chain comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and

[0201] ii) a first light chain comprising a first light chain variable region (VL) and a first light chain constant region (CL); and the second binding arm comprises

[0202] i) a second heavy chain comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and

[0203] ii) a second light chain comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0204] In some embodiments, the first binding arm is derived from a full-length antibody. In some embodiments, the first binding arm is derived from a monoclonal antibody. In some embodiments, the first binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the second binding arm is derived from a full-length antibody. In some embodiments, the second binding arm is derived from a monoclonal antibody. In some embodiments, the second binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first binding arm and the second binding arm are derived from a full-length antibody, for example, from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first binding arm and the second binding arm are derived from a monoclonal antibody.

[0205] In some embodiments, each of the first heavy chain constant region and the second heavy chain constant region (CH) comprises one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region, and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region, and a CH3 region.

[0206] In some embodiments, each of the first heavy chain constant region and the second heavy chain constant region (CH) comprises a CH3 region, and wherein the two CH3 regions comprise an asymmetric mutation.

[0207] In some embodiments, in the first heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and in the second heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and wherein the first heavy chain and the second heavy chain are not replaced in the same position.

[0208] In some embodiments, (i) in the first heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) in the first heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0209] In some embodiments, the binding agent induces Fc-mediated effector function to a lesser extent than another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CH) containing human IgG1 hinge, CH2, and CH3 regions.

[0210] In some embodiments, the first heavy chain constant region and the second heavy chain constant region (CH) are modified such that the antibody induces Fc-mediated effector function to a lesser extent than an identical antibody except that it comprises an unmodified first heavy chain constant region and a second heavy chain constant region (CH).

[0211] In some embodiments, each of the unmodified first heavy chain constant region and the second heavy chain constant region (CH) comprises the amino acid sequence shown in SEQ ID NO:47.

[0212] In some embodiments, the Fc-mediated effector function is measured by binding to an Fcγ receptor, binding to C1q, or induction of Fc-mediated cross-linking of Fcγ receptors.

[0213] In some embodiments, the Fc-mediated effector function is measured by binding to CIq.

[0214] In some embodiments, the first heavy chain constant region and the second heavy chain constant region have been modified such that binding of C1q to the antibody is reduced compared to the wild-type antibody, preferably by at least 70%, at least 80%, at least 90%, at least 95%, at least 97% or 100%, wherein C1q binding is preferably determined by ELISA.

[0215] In some embodiments, in at least one of the first heavy chain constant region and the second heavy chain constant region (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, P331 and G236 in the human IgG1 heavy chain according to EU numbering are not L, L, D, N, P and G, respectively.

[0216] In some embodiments, in the first and second heavy chains, the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively.

[0217] In some embodiments, in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and / or in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0218] In some embodiments,

[0219] (i) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively;

[0220] (ii) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively; or

[0221] (iii) in one of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the other of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0222] In some embodiments, the positions of both the first heavy chain constant region and the second heavy chain constant region corresponding to positions L234 and L235 in the human IgG1 heavy chain according to EU numbering are F and E, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0223] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0224] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R.

[0225] In some embodiments, the constant region of the first and / or second heavy chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:47.

[0226] In some embodiments,

[0227] a) the constant region of the first heavy chain comprises the amino acid sequence shown in SEQ ID NO: 54; and

[0228] b) the constant region of the second heavy chain comprises the amino acid sequence shown in SEQ ID NO:52.

[0229] In some embodiments, the binding agent comprises a kappa (κ) light chain constant region.

[0230] In some embodiments, the binding agent comprises a lambda (λ) light chain constant region.

[0231] In some embodiments, the first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0232] In some embodiments, the second light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0233] In some embodiments,

[0234] (i) the first light chain constant region and the second light chain constant region are kappa (κ) light chain constant regions,

[0235] (ii) the first light chain constant region and the second light chain constant region are lambda (λ) light chain constant regions,

[0236] (iii) the first light chain constant region is a kappa (κ) light chain constant region, and the second light chain constant region is a lambda (λ) light chain constant region, or (iv) the first light chain constant region is a lambda (λ) light chain constant region, and the second light chain constant region is a kappa (κ) light chain constant region.

[0237] In some embodiments, the kappa (κ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:55.

[0238] In some embodiments, the lambda (λ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:56.

[0239] In some embodiments, the binding agent has an isotype selected from IgG1, IgG2, IgG3, and IgG4. In one embodiment, the isotype is selected from human IgG1, human IgG2, human IgG3, and human IgG4.

[0240] In some embodiments, the binding agent is a full length IgG1 antibody.

[0241] In some embodiments, the binding agent is an antibody of the IgG1m(f) allotype.

[0242] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0243] The first binding arm comprises

[0244] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first VH comprises a first HCDR1, HCDR2 and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2 and LCDR3 sequence, wherein the first HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 76, 77 and 78, respectively, and the first LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 79, 80 and 81, respectively;

[0245] and the second binding arm comprises

[0246] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively;

[0247] wherein in the first CH, positions L234, L235, and G236 in the human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the second CH, positions L234, L235, and D265 in the human IgG1 heavy chain according to EU numbering are F, E, and A; and

[0248] wherein in the first CH, the amino acid in the position corresponding to F405 in human IgG1 heavy chain according to EU numbering is L, and in the second CH, the amino acid in the position corresponding to K409 in human IgG1 heavy chain according to EU numbering is R.

[0249] In some embodiments, the binding agent comprises

[0250] i) a first heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 21,

[0251] ii) a first light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 22,

[0252] iii) a second heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 19; and

[0253] iv) a second light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:20.

[0254] In some embodiments, the binding agent comprises

[0255] i) a first heavy chain comprising the amino acid sequence shown in SEQ ID NO: 21,

[0256] ii) a first light chain comprising the amino acid sequence shown in SEQ ID NO: 22,

[0257] iii) a second heavy chain comprising the amino acid sequence shown in SEQ ID NO: 19; and

[0258] iv) a second light chain comprising the amino acid sequence shown in SEQ ID NO: 20.

[0259] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR3 sequence, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO: 90. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR2 sequence, and the LCDR2 sequence comprises the sequence shown in SEQ ID NO: 89. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR1 sequence, and the LCDR1 sequence comprises the sequence shown in SEQ ID NO: 88. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences, wherein LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NO: 88, 89, and 90, respectively. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 91, 92 and 90, respectively.

[0260] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR3 sequence and a light chain variable region (VL) comprising a LCDR3 sequence, wherein the HCDR3 sequence comprises the sequence shown in SEQ ID NO:4, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO:90.

[0261] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 88, 89 and 90, respectively.

[0262] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 65 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 91, 92 and 90, respectively.

[0263] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 3 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 88, 89 and 90, respectively.

[0264] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 25 (positions 1 to 115), and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 26 (positions 1 to 111).

[0265] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:25 (positions 1 to 115).

[0266] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 25 (positions 1 to 115).

[0267] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:26 (positions 1 to 111).

[0268] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 26 (positions 1 to 111).

[0269] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:25 (positions 1 to 115), and VL comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:26 (positions 1 to 111). In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 25 (positions 1 to 115), and VL comprises a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 26 (positions 1 to 111). In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 25 (positions 1 to 115), and VL comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 26 (positions 1 to 111). In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 95% identical to the sequence shown in SEQ ID NO:25 (positions 1 to 115), and VL comprises a sequence that is at least 95% identical to the sequence shown in SEQ ID NO:26 (positions 1 to 111).

[0270] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO:25 (positions 1 to 115), and VL comprises the sequence shown in SEQ ID NO:26 (positions 1 to 111).

[0271] In some embodiments, the first antigen binding region that binds to EpCAM comprises the heavy chain variable region and light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region (VH) and / or light chain variable region (VL) as shown above and / or has the EpCAM specificity of the antibody.

[0272] In some embodiments, the second antigen binding region that binds to CD137 is as shown above.

[0273] In some embodiments,

[0274] a) the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 90, and

[0275] b) The second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 18.

[0276] In some embodiments,

[0277] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises the HCDR3 sequence shown in SEQ ID NO: 4, and the light chain variable region (VL) comprises the LCDR3 sequence shown in SEQ ID NO: 90, and

[0278] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising the HCDR3 sequence shown in SEQ ID NO: 14, and the light chain variable region (VL) comprising the LCDR3 sequence shown in SEQ ID NO: 18.

[0279] In some embodiments,

[0280] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 88, 89 and 90, respectively; and

[0281] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0282] In some embodiments,

[0283] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 65 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 91, 92 and 90, respectively; and

[0284] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 69, 70 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 72, 73 and 18, respectively.

[0285] In some embodiments,

[0286] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 3 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 88, 89 and 90, respectively; and

[0287] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 75, 13 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0288] In some embodiments,

[0289] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 25 (positions 1 to 115), and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 26 (positions 1 to 111); and

[0290] b) the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 11, and the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 15.

[0291] In some embodiments,

[0292] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 25 (positions 1 to 115), and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 26 (positions 1 to 111); and

[0293] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 11, and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 15.

[0294] In some embodiments,

[0295] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 25 (positions 1 to 115), and VL comprises the sequence shown in SEQ ID NO: 26 (positions 1 to 111); and

[0296] b) The second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 11, and VL comprises the sequence shown in SEQ ID NO: 15.

[0297] In some embodiments, the first antigen-binding region that binds to EpCAM comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to EpCAM as shown above and / or has the EpCAM specificity of the antibody, and the second antigen-binding region that binds to CD137 comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for CD137 binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to CD137 as shown above and / or has the CD137 specificity of the antibody.

[0298] In some embodiments, the variable region comprises three complementarity determining regions (CDR1, CDR2, and CDR3) and four framework regions (FR1, FR2, FR3, and FR4).

[0299] In some embodiments, the complementarity determining regions and the framework regions are arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0300] In some embodiments, the binding agent is in the form of a full-length antibody or an antibody fragment.

[0301] In some embodiments, the binding agent is a multispecific binding agent, such as a bispecific binding agent.

[0302] In some embodiments, the binding agent is a multispecific antibody, such as a bispecific antibody.

[0303] In some embodiments, the binding agent comprises (i) a first heavy chain variable region (VH) and a first light chain variable region (VL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0304] (ii) a second heavy chain variable region (VH) and a second light chain variable region (VL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0305] In some embodiments, the binding agent comprises

[0306] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0307] ii) a polypeptide containing a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and a polypeptide containing a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0308] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0309] The first binding arm comprises

[0310] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL);

[0311] and the second binding arm comprises

[0312] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0313] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0314] The first binding arm comprises

[0315] i) a first heavy chain comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and

[0316] ii) a first light chain comprising a first light chain variable region (VL) and a first light chain constant region (CL); and the second binding arm comprises

[0317] i) a second heavy chain comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and

[0318] ii) a second light chain comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0319] In some embodiments, the first binding arm is derived from a full-length antibody. In some embodiments, the first binding arm is derived from a monoclonal antibody. In some embodiments, the first binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the second binding arm is derived from a full-length antibody. In some embodiments, the second binding arm is derived from a monoclonal antibody. In some embodiments, the second binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first binding arm and the second binding arm are derived from a full-length antibody, for example, from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first binding arm and the second binding arm are derived from a monoclonal antibody.

[0320] In some embodiments, each of the first heavy chain constant region and the second heavy chain constant region (CH) comprises one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region, and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region, and a CH3 region.

[0321] In some embodiments, each of the first heavy chain constant region and the second heavy chain constant region (CH) comprises a CH3 region, and wherein the two CH3 regions comprise an asymmetric mutation.

[0322] In some embodiments, in the first heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and in the second heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and wherein the first heavy chain and the second heavy chain are not replaced in the same position.

[0323] In some embodiments, (i) in the first heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) in the first heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0324] In some embodiments, the binding agent induces Fc-mediated effector function to a lesser extent than another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CH) containing human IgG1 hinge, CH2, and CH3 regions.

[0325] In some embodiments, the first heavy chain constant region and the second heavy chain constant region (CH) are modified such that the antibody induces Fc-mediated effector function to a lesser extent than an identical antibody except that it comprises an unmodified first heavy chain constant region and a second heavy chain constant region (CH).

[0326] In some embodiments, each of the unmodified first heavy chain constant region and the second heavy chain constant region (CH) comprises the amino acid sequence shown in SEQ ID NO:47.

[0327] In some embodiments, the Fc-mediated effector function is measured by binding to an Fcγ receptor, binding to C1q, or induction of Fc-mediated cross-linking of Fcγ receptors.

[0328] In some embodiments, the Fc-mediated effector function is measured by binding to CIq.

[0329] In some embodiments, the first heavy chain constant region and the second heavy chain constant region have been modified such that binding of C1q to the antibody is reduced, preferably by at least 70%, at least 80%, at least 90%, at least 95%, at least 97% or 100%, compared to the wild-type antibody, wherein C1q binding is preferably determined by ELISA.

[0330] In some embodiments, in at least one of the first heavy chain constant region and the second heavy chain constant region (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, P331 and G236 in the human IgG1 heavy chain according to EU numbering are not L, L, D, N, P and G, respectively.

[0331] In some embodiments, in the first and second heavy chains, the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively.

[0332] In some embodiments, in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and / or in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0333] In some embodiments,

[0334] (i) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively;

[0335] (ii) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively; or

[0336] (iii) in one of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the other of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0337] In some embodiments, the positions of both the first and second heavy chain constant regions corresponding to positions L234 and L235 in the human IgG1 heavy chain according to EU numbering are F and E, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0338] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0339] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R.

[0340] In some embodiments, the constant region of the first heavy chain and / or the second heavy chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:47.

[0341] In some embodiments,

[0342] a) the constant region of the first heavy chain comprises the amino acid sequence shown in SEQ ID NO: 54; and

[0343] b) the constant region of the second heavy chain comprises the amino acid sequence shown in SEQ ID NO:52.

[0344] In some embodiments, the binding agent comprises a kappa (κ) light chain constant region.

[0345] In some embodiments, the binding agent comprises a lambda (λ) light chain constant region.

[0346] In some embodiments, the first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0347] In some embodiments, the second light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0348] In some embodiments,

[0349] (i) the first light chain constant region and the second light chain constant region are kappa (κ) light chain constant regions,

[0350] (ii) the first light chain constant region and the second light chain constant region are lambda (λ) light chain constant regions,

[0351] (iii) the first light chain constant region is a kappa (κ) light chain constant region, and the second light chain constant region is a lambda (λ) light chain constant region, or (iv) the first light chain constant region is a lambda (λ) light chain constant region, and the second light chain constant region is a kappa (κ) light chain constant region.

[0352] In some embodiments, the kappa (κ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:55.

[0353] In some embodiments, the lambda (λ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:56.

[0354] In some embodiments, the binding agent has an isotype selected from IgG1, IgG2, IgG3, and IgG4. In one embodiment, the isotype is selected from human IgG1, human IgG2, human IgG3, and human IgG4.

[0355] In some embodiments, the binding agent is a full length IgG1 antibody.

[0356] In some embodiments, the binding agent is an antibody of the IgG1m(f) allotype.

[0357] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0358] The first binding arm comprises

[0359] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first VH comprises a first HCDR1, HCDR2 and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2 and LCDR3 sequence, wherein the first HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the first LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 88, 89 and 90, respectively;

[0360] and the second binding arm comprises

[0361] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively;

[0362] wherein in the first CH, positions L234, L235, and G236 in the human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the second CH, positions L234, L235, and D265 in the human IgG1 heavy chain according to EU numbering are F, E, and A; and

[0363] wherein in the first CH, the amino acid in the position corresponding to F405 in human IgG1 heavy chain according to EU numbering is L, and in the second CH, the amino acid in the position corresponding to K409 in human IgG1 heavy chain according to EU numbering is R.

[0364] In some embodiments, the binding agent comprises

[0365] i) a first heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 25,

[0366] ii) a first light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 26,

[0367] iii) a second heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 19; and

[0368] iv) a second light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:20.

[0369] In some embodiments, the binding agent comprises

[0370] i) a first heavy chain comprising the amino acid sequence shown in SEQ ID NO: 25,

[0371] ii) a first light chain comprising the amino acid sequence shown in SEQ ID NO: 26,

[0372] iii) a second heavy chain comprising the amino acid sequence shown in SEQ ID NO: 19; and

[0373] iv) a second light chain comprising the amino acid sequence shown in SEQ ID NO: 20.

[0374] In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR3 sequence, and the HCDR3 sequence comprises the sequence shown in SEQ ID NO: 4. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR2 sequence, and the HCDR2 sequence comprises the sequence shown in SEQ ID NO: 93. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR1 sequence, and the HCDR1 sequence comprises the sequence shown in SEQ ID NO: 2. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NO: 2, 93, and 4, respectively. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 96, and 66, respectively. In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 93, and 66, respectively.

[0375] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR3 sequence, and the LCDR3 sequence comprises the sequence shown in SEQ ID NO: 8. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR2 sequence, and the LCDR2 sequence comprises the sequence shown in SEQ ID NO: 95. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR1 sequence, and the LCDR1 sequence comprises the sequence shown in SEQ ID NO: 94. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences, wherein LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 94, 95, and 8, respectively. In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 97, 98 and 8, respectively.

[0376] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 93 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 94, 95 and 8, respectively.

[0377] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 96 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 97, 98 and 8, respectively.

[0378] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 93 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 94, 95 and 8, respectively.

[0379] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and / or a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 27 (positions 1 to 115), and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 28 (positions 1 to 108).

[0380] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:27 (positions 1 to 115).

[0381] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO: 27 (positions 1 to 115).

[0382] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:28 (positions 1 to 108).

[0383] In some embodiments, the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the sequence shown in SEQ ID NO: 28 (positions 1 to 108).

[0384] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:27 (positions 1 to 115), and VL comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:28 (positions 1 to 108). In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 27 (positions 1 to 115), and VL comprises a sequence having at least 80% identity with the sequence shown in SEQ ID NO: 28 (positions 1 to 108). In some embodiments, the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 27 (positions 1 to 115), and VL comprises a sequence having at least 90% identity with the sequence shown in SEQ ID NO: 28 (positions 1 to 108). In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 95% identical to the sequence shown in SEQ ID NO:27 (positions 1 to 115), and VL comprises a sequence that is at least 95% identical to the sequence shown in SEQ ID NO:28 (positions 1 to 108).

[0385] In some embodiments, the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO:27 (positions 1 to 115), and VL comprises the sequence shown in SEQ ID NO:28 (positions 1 to 108).

[0386] In some embodiments, the first antigen binding region that binds to EpCAM comprises the heavy chain variable region and light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region (VH) and / or light chain variable region (VL) as shown above and / or has the EpCAM specificity of the antibody.

[0387] In some embodiments, the second antigen binding region that binds to CD137 is as shown above.

[0388] In some embodiments,

[0389] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 93 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 94, 95 and 8, respectively; and

[0390] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0391] In some embodiments,

[0392] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 64, 96 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 97, 98 and 8, respectively; and

[0393] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 69, 70 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 72, 73 and 18, respectively.

[0394] In some embodiments,

[0395] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 74, 93 and 66, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 94, 95 and 8, respectively; and

[0396] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 75, 13 and 71, respectively, and LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0397] In some embodiments,

[0398] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region (VH) comprises the HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 27 (positions 1 to 115), and the light chain variable region (VL) comprises the LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 28 (positions 1 to 108); and

[0399] b) the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences of SEQ ID NO: 11, and the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences of SEQ ID NO: 15.

[0400] In some embodiments,

[0401] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 27 (positions 1 to 115), and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 28 (positions 1 to 108); and

[0402] b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 11, and VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 15.

[0403] In some embodiments,

[0404] a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 27 (positions 1 to 115), and VL comprises the sequence shown in SEQ ID NO: 28 (positions 1 to 108); and

[0405] b) The second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 11, and VL comprises the sequence shown in SEQ ID NO: 15.

[0406] In some embodiments, the first antigen-binding region that binds to EpCAM comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for EpCAM binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to EpCAM as shown above and / or has the EpCAM specificity of the antibody, and the second antigen-binding region that binds to CD137 comprises the heavy chain variable region and the light chain variable region of such an antibody: it competes for CD137 binding with an antibody comprising the heavy chain variable region or the light chain variable region or a combination thereof that binds to CD137 as shown above and / or has the CD137 specificity of the antibody.

[0407] In some embodiments, the variable region comprises three complementarity determining regions (CDR1, CDR2, and CDR3) and four framework regions (FR1, FR2, FR3, and FR4).

[0408] In some embodiments, the complementarity determining regions and the framework regions are arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0409] In some embodiments, the binding agent is in the form of a full-length antibody or an antibody fragment.

[0410] In some embodiments, the binding agent is a multispecific binding agent, such as a bispecific binding agent.

[0411] In some embodiments, the binding agent is a multispecific antibody, such as a bispecific antibody.

[0412] In some embodiments, the binding agent comprises (i) a first heavy chain variable region (VH) and a first light chain variable region (VL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0413] (ii) a second heavy chain variable region (VH) and a second light chain variable region (VL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0414] In some embodiments, the binding agent comprises

[0415] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first heavy chain variable region (VH) and the first light chain variable region (VL) form the first antigen binding region that binds to EpCAM; and

[0416] ii) a polypeptide containing a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and a polypeptide containing a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second heavy chain variable region (VH) and the second light chain variable region (VL) form the second antigen binding region that binds to CD137.

[0417] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0418] The first binding arm comprises

[0419] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL);

[0420] and the second binding arm comprises

[0421] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0422] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0423] The first binding arm comprises

[0424] i) a first heavy chain comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and

[0425] ii) a first light chain comprising a first light chain variable region (VL) and a first light chain constant region (CL); and the second binding arm comprises

[0426] i) a second heavy chain comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and

[0427] ii) a second light chain comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0428] In some embodiments, the first binding arm is derived from a full-length antibody. In some embodiments, the first binding arm is derived from a monoclonal antibody. In some embodiments, the first binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the second binding arm is derived from a full-length antibody. In some embodiments, the second binding arm is derived from a monoclonal antibody. In some embodiments, the second binding arm is derived from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first binding arm and the second binding arm are derived from a full-length antibody, for example, from a full-length IgG1, λ (lambda) or IgG1, κ (kappa) antibody. In some embodiments, the first binding arm and the second binding arm are derived from a monoclonal antibody.

[0429] In some embodiments, each of the first heavy chain constant region and the second heavy chain constant region (CH) comprises one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region, and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region, and a CH3 region.

[0430] In some embodiments, each of the first heavy chain constant region and the second heavy chain constant region (CH) comprises a CH3 region, and wherein the two CH3 regions comprise an asymmetric mutation.

[0431] In some embodiments, in the first heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and in the second heavy chain constant region (CH), at least one amino acid in a position corresponding to a position selected from the group consisting of T366, L368, K370, D399, F405, Y407 and K409 in a human IgG1 heavy chain according to EU numbering has been replaced, and wherein the first heavy chain and the second heavy chain are not replaced in the same position.

[0432] In some embodiments, (i) in the first heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) in the first heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0433] In some embodiments, the binding agent induces Fc-mediated effector function to a lesser extent than another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CH) containing human IgG1 hinge, CH2, and CH3 regions.

[0434] In some embodiments, the first heavy chain constant region and the second heavy chain constant region (CH) are modified such that the antibody induces Fc-mediated effector function to a lesser extent than an identical antibody except that it comprises an unmodified first heavy chain constant region and a second heavy chain constant region (CH).

[0435] In some embodiments, each of the unmodified first heavy chain constant region and the second heavy chain constant region (CH) comprises the amino acid sequence shown in SEQ ID NO:47.

[0436] In some embodiments, the Fc-mediated effector function is measured by binding to an Fcγ receptor, binding to C1q, or induction of Fc-mediated cross-linking of Fcγ receptors.

[0437] In some embodiments, the Fc-mediated effector function is measured by binding to CIq.

[0438] In some embodiments, the first heavy chain constant region and the second heavy chain constant region have been modified such that binding of C1q to the antibody is reduced, preferably by at least 70%, at least 80%, at least 90%, at least 95%, at least 97% or 100%, compared to the wild-type antibody, wherein C1q binding is preferably determined by ELISA.

[0439] In some embodiments, in at least one of the first heavy chain constant region and the second heavy chain constant region (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, P331 and G236 in the human IgG1 heavy chain according to EU numbering are not L, L, D, N, P and G, respectively.

[0440] In some embodiments, in the first and second heavy chains, the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively.

[0441] In some embodiments, in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and / or in the first heavy chain constant region and / or the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0442] In some embodiments,

[0443] (i) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively;

[0444] (ii) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively; or

[0445] (iii) in one of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the other of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0446] In some embodiments, the positions of both the first heavy chain constant region and the second heavy chain constant region corresponding to positions L234 and L235 in the human IgG1 heavy chain according to EU numbering are F and E, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0447] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0448] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R.

[0449] In some embodiments, the constant region of the first heavy chain and / or the second heavy chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:47.

[0450] In some embodiments,

[0451] a) the constant region of the first heavy chain comprises the amino acid sequence shown in SEQ ID NO: 54; and

[0452] b) the constant region of the second heavy chain comprises the amino acid sequence shown in SEQ ID NO:52.

[0453] In some embodiments, the binding agent comprises a kappa (κ) light chain constant region.

[0454] In some embodiments, the binding agent comprises a lambda (λ) light chain constant region.

[0455] In some embodiments, the first light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0456] In some embodiments, the second light chain constant region is a kappa (κ) light chain constant region or a lambda (λ) light chain constant region.

[0457] In some embodiments,

[0458] (i) the first light chain constant region and the second light chain constant region are kappa (κ) light chain constant regions,

[0459] (ii) the first light chain constant region and the second light chain constant region are lambda (λ) light chain constant regions,

[0460] (iii) the first light chain constant region is a kappa (κ) light chain constant region, and the second light chain constant region is a lambda (λ) light chain constant region, or (iv) the first light chain constant region is a lambda (λ) light chain constant region, and the second light chain constant region is a kappa (κ) light chain constant region.

[0461] In some embodiments, the kappa (κ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:55.

[0462] In some embodiments, the lambda (λ) light chain comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO:56.

[0463] In some embodiments, the binding agent has an isotype selected from IgG1, IgG2, IgG3, and IgG4. In one embodiment, the isotype is selected from human IgG1, human IgG2, human IgG3, and human IgG4.

[0464] In some embodiments, the binding agent is a full length IgG1 antibody.

[0465] In some embodiments, the binding agent is an antibody of the IgG1m(f) allotype.

[0466] In some embodiments, the binding agent is an antibody comprising a first binding arm and a second binding arm, wherein the first binding arm comprises the first antigen binding region that binds to EpCAM and the second binding arm comprises the second antigen binding region that binds to CD137, wherein:

[0467] The first binding arm comprises

[0468] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first VH comprises a first HCDR1, HCDR2 and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2 and LCDR3 sequence, wherein the first HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 93 and 4, respectively, and the first LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 94, 95 and 8, respectively;

[0469] and the second binding arm comprises

[0470] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively;

[0471] wherein in the first CH, positions L234, L235, and G236 in the human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the second CH, positions L234, L235, and D265 in the human IgG1 heavy chain according to EU numbering are F, E, and A; and

[0472] wherein in the first CH, the amino acid in the position corresponding to F405 in human IgG1 heavy chain according to EU numbering is L, and in the second CH, the amino acid in the position corresponding to K409 in human IgG1 heavy chain according to EU numbering is R.

[0473] In some embodiments, the binding agent comprises

[0474] i) a first heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 27,

[0475] ii) a first light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 28,

[0476] iii) a second heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 19; and

[0477] iv) a second light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:20.

[0478] In some embodiments, the binding agent comprises

[0479] i) a first heavy chain comprising the amino acid sequence shown in SEQ ID NO: 27,

[0480] ii) a first light chain comprising the amino acid sequence shown in SEQ ID NO: 28,

[0481] iii) a second heavy chain comprising the amino acid sequence shown in SEQ ID NO: 19; and

[0482] iv) a second light chain comprising the amino acid sequence shown in SEQ ID NO: 20.

[0483] In another aspect, the disclosure provides a binding agent comprising a first binding arm comprising a first antigen binding region and a first heavy chain constant region comprising a constant heavy chain 2 (CH2) region, and a second binding arm comprising a second antigen binding region and a second heavy chain constant region comprising a constant heavy chain 2 (CH2) region,

[0484] wherein at least one of the first and second antigen binding regions binds to EpCAM, and wherein in at least one of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

[0485] In some embodiments, in the first heavy chain constant region and / or the second heavy chain constant region, the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain according to EU numbering are F, E, and R, respectively.

[0486] In some embodiments, in both the first heavy chain constant region and / or the second heavy chain constant region, the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain according to EU numbering are F, E, and R, respectively.

[0487] In some embodiments, in one of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and G236 in the human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the other of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain according to EU numbering are F, E, and A, respectively.

[0488] In some embodiments, both the first and second antigen binding regions bind to EpCAM.

[0489] In some embodiments, one of the first and second antigen binding regions binds to EpCAM and the other of the first and second antigen binding regions binds to an antigen other than EpCAM.

[0490] In some embodiments, one of the first and second antigen binding regions binds to EpCAM and the other of the first and second antigen binding regions binds to CD137.

[0491] In another aspect, the disclosure provides a binding agent comprising a first binding arm comprising a first antigen binding region and a first heavy chain constant region comprising a constant heavy chain 2 (CH2) region, and a second binding arm comprising a second antigen binding region and a second heavy chain constant region comprising a constant heavy chain 2 (CH2) region,

[0492] wherein at least one of the first and second antigen binding regions binds to CD137, and wherein in at least one of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235, and G236 in the human IgG1 heavy chain according to EU numbering are F, E, and R, respectively.

[0493] In some embodiments, in the first heavy chain constant region and / or the second heavy chain constant region, the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain according to EU numbering are F, E, and R, respectively.

[0494] In some embodiments, in both the first heavy chain constant region and / or the second heavy chain constant region, the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain according to EU numbering are F, E, and R, respectively.

[0495] In some embodiments, in one of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and G236 in the human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the other of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in the human IgG1 heavy chain according to EU numbering are F, E, and A, respectively.

[0496] In some embodiments, both the first and second antigen binding regions bind to CD137.

[0497] In some embodiments, one of the first and second antigen binding regions binds to CD137 and the other of the first and second antigen binding regions binds to an antigen other than CD137.

[0498] In some embodiments, one of the first and second antigen binding regions binds to CD137 and the other of the first and second antigen binding regions binds to EpCAM.

[0499] In some embodiments, the antigen binding region that binds to EpCAM and / or the antigen binding region that binds to CD137 is as described herein.

[0500] In some embodiments, EpCAM is human EpCAM.

[0501] In some embodiments, the antigen binding region that binds to EpCAM binds to EpCAM expressed on tumor cells.

[0502] In some embodiments, the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively.

[0503] In some embodiments, the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:1, and VL comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:5.

[0504] In some embodiments, the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO:1, and VL comprises the sequence shown in SEQ ID NO:5.

[0505] In some embodiments, CD137 is human CD137.

[0506] In some embodiments, the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0507] In some embodiments, the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:11, and VL comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:15.

[0508] In some embodiments, the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein VH comprises the sequence shown in SEQ ID NO: 11, and VL comprises the sequence shown in SEQ ID NO: 15.

[0509] In some embodiments, the binding agent comprises an antigen binding region that binds to EpCAM and an antigen binding region that binds to CD137, wherein:

[0510] a) the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and

[0511] b) the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0512] In some embodiments, the binding agent is a bivalent binding agent.

[0513] In some embodiments, the binding agent comprises an Fc region.

[0514] In some embodiments, the binding agent is in the form of an antibody, such as a full-length antibody.

[0515] In some embodiments, the binding agent comprises a first binding arm comprising an antigen binding region that binds to EpCAM and a second binding arm comprising an antigen binding region that binds to CD137, wherein:

[0516] The first binding arm comprises

[0517] i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL);

[0518] and the second binding arm comprises

[0519] iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL).

[0520] In some embodiments,

[0521] The first VH comprises a first HCDR1, HCDR2, and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2, and LCDR3 sequence, wherein the first HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3, and 4, respectively, and the first LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7, and 8, respectively; and

[0522] The second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

[0523] In some embodiments,

[0524] the first VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 1, and the first VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 5; and

[0525] The second VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:11, and the second VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:15.

[0526] In some embodiments,

[0527] The first VH comprises the amino acid sequence shown in SEQ ID NO: 1, and the first VL comprises the amino acid sequence shown in SEQ ID NO: 5; and

[0528] The second VH comprises the amino acid sequence shown in SEQ ID NO:11, and the second VL comprises the amino acid sequence shown in SEQ ID NO:15.

[0529] In some embodiments, each of the first heavy chain constant region and the second heavy chain constant region (CH) comprises a CH3 region, and wherein the two CH3 regions comprise an asymmetric mutation.

[0530] In some embodiments, (i) in the first heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) in the first heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0531] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein (i) the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) the position of the first heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and the position of the second heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

[0532] In some embodiments, in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein the position of the first heavy chain constant region corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and the position of the second heavy chain constant region corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R.

[0533] In another aspect, the disclosure provides a polynucleotide or set of polynucleotides encoding a binding agent as set forth herein.

[0534] In another aspect, the disclosure provides a pharmaceutical composition comprising a binding agent as set forth herein or a polynucleotide as set forth herein.

[0535] In another aspect, the disclosure provides a method for treating a subject, comprising administering to the subject a binding agent as set forth herein, a polynucleotide as set forth herein, or a pharmaceutical composition as set forth herein.

[0536] In some embodiments, the method is a method for treating or preventing cancer in a subject.

[0537] In some embodiments, the subject is a human.

[0538] In another aspect, the disclosure provides a binding agent as indicated herein, a polynucleotide as indicated herein, or a pharmaceutical composition as indicated herein for use in medicine, e.g., as a medicament.

[0539] In some embodiments, a binding agent as set forth herein, a polynucleotide as set forth herein, or a pharmaceutical composition as set forth herein is used for therapeutic or prophylactic treatment of a disease or disorder.

[0540] In some embodiments, the disease or condition is cancer.

[0541] In another aspect, the disclosure provides a binding agent as set forth herein, a polynucleotide as set forth herein, or a pharmaceutical composition as set forth herein for use in treating or preventing cancer in a subject.

[0542] In some embodiments, the subject is a human. BRIEF DESCRIPTION OF THE DRAWINGS

[0543] Figure 1 : Relative EpCAM expression on tumor cells

[0544] Figure 1 Relative EpCAM expression on T84, DiFi, HPAF-II, NCI-N87, Calu-3, NCI-H747 and A549 tumor cell lines as determined by flow cytometry is shown. The data shown are the delta geometric mean fluorescence intensity (gMFI) for each tumor cell line, calculated as follows: geometric mean fluorescence intensity (APC) of EpCAM antibody - geometric mean fluorescence (APC) of non-binding control antibody.

[0545] Figure 2 : Binding of bivalent EpCAM antibodies and their monovalent counterparts to DiFi, HPAF-II or A549 cells.

[0546] Monovalent and bivalent binding of EpCAM antibodies to DiFi, HPAF-II or A549 cell lines was determined by flow cytometry. IgG1-b12-FEAL was included as a negative control (open squares) in all experiments. Data shown are mean fluorescence intensity (MFI; R-phycoerythrin [PE]) ± standard deviation (SD) of replicate measurements of one representative experiment.

[0547] A. Binding of bsIgG1-b12-FEALxEpCAM-A37-FEAR (filled circles) and IgG1-EpCAM-A37-FEAR (open triangles) antibodies to DiFi, HPAF-II, or A549 cells. B. Binding of bsIgG1-b12-FEALxEpCAM-C52-FEAR (filled circles) and IgG1-EpCAM-C52-FEAR (open triangles) antibodies to DiFi, HPAF-II, or A549 cells. C. Binding of bsIgG1-v12-FEALxEpCAM-UBS-54-FEAR (filled circles) and IgG1-EpCAM-UBS-54-FEAR (open triangles) antibodies to DiFi, HPAF-II, or A549 cells. D. Binding of IgG1-EpCAM-323-A3-FEAR (open triangles) antibody to DiFi or HPAF-II cells.

[0548] E. Binding of bsIgG1-CD137-009-HC7LC2-FEAL / EpCAM-A37-FEAR and bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR as well as non-binding control bispecific antibodies bsIgG1-b12-FERL / CD137-HC7LC2-FEAR and bsIgG1-b12-FERL / b12-FEAR to DiFi cells.

[0549] Figure 3 : Binding of EpCAM antibodies to full-length human, cynomolgus monkey or mouse EpCAM transfected into CHO-S cells.

[0550] Binding of monovalent and bivalent EpCAM antibodies was analyzed using CHO-S cells transiently transfected with full-length human, cynomolgus monkey or mouse EpCAM. As a negative control, binding to non-transfected CHO-WT cells was evaluated. Data are presented as geometric mean fluorescence intensity (gMFI) R-PE values ​​± SD of two technical replicates. A. Binding of IgG1-EpCAM-UBS-54FEAR, IgG1-EpCAM-A37-FEAR, IgG1-EpCAM-C52-FEAR and IgG1-EpCAM-343-A3.

[0551] B. Binding of bsIgG1-b12-FEAL / EpCAM-UBS-54-FEAR, bsIgG1-EpCAM-A37-FERL / b12-FEAR, bsIgG1-b12-FEAL / EpCAM-C52-FEAR, and bsIgG1-b12-FEAM-323-A3-FEAR.

[0553] Figure 4 : Induction of 4-1BB-dependent luciferase activity by EpCAMx4-1BB bispecific antibody in a cell-based reporter assay.

[0554] In the presence of serially diluted BsIgG1-CD137-005-FEAR / EpCAM-323-A3-FEAL, HEK293_NKF_h4-1BB_gfp_luc reporter cells were co-cultured with OV-90-SC12 cells expressing EpCAM overnight, or cultured alone (culture medium) overnight. Luciferase activity was quantified by luminescence measurement. The multiple induction of luciferase activity relative to the culture without antibody (dashed line) is shown. Error bars show the SD of duplicate wells. Data from a representative experiment in three is shown.

[0555] Figure 5 : Enhancement of in vitro PBMC proliferation by EpCAMx4-1BB bispecific antibody in PBMC-DiFi cell co-culture.

[0556] EpCAMx4-1BB bispecific antibodies were tested in vitro PBMC proliferation assays using DiFi cells expressing EpCAM co-cultured with CFSE-labeled PBMCs. Cells were cultured for 96 hours with or without adding a specified concentration of EpCAMx4-1BB or EpCAMxb12 bispecific antibodies or non-binding control IgG1-b12-FEAL in the presence of anti-CD3 (0.1 μg / mL). The number of CFSE-positive cells was extracted and used to calculate the division index. The data shown are the average division index ± SD of repeated measurements obtained from a representative experiment. A. The division index of PBMC proliferation induced by bsIgG1-b12-FEAL / EpCAM-UBS54-FEAR (solid triangles) and bsIgG1-CD137-009-HC7LC2-FEAL / EpCAM-IbS54-FEAR (solid squares) antibodies. B. The division index of PBMC proliferation induced by bsIgG1-b12-FEAL / EpCAM-A37-FEAR (solid triangle) and bsIgG1-CD137-009-HC7LC2-FEAL / EpCAM-A37-FEAR (solid square) antibodies. C. The division index of PBMC proliferation induced by bsIgG1-b12-FEAL / EpCAM-C52-FEAR (solid triangle) and bsIgG1-CD137-009-HC7LC2-FEAL / EpCAM-C52-FEAR (solid square) antibodies. D. The division index of PBMC proliferation induced by bsIgG1-b12-FEAL / EpCAM-23-A3-FEAR (solid triangle) and bsIgG1-CD137-009-HC7LC2-FEAL / EpCAM-323-A3-FEAR (solid square) antibodies.

[0557] Figure 6 : Enhancement of in vitro CD4+ and CD8+ T cell proliferation by EpCAMx4-1BB bispecific antibody in PBMC-DiFi cell co-cultures.

[0558] EpCAMx4-1BB bispecific antibodies were tested in vitro T cell proliferation assays using DiFi cells expressing EpCAM co-cultured with CFSE-labeled PBMC. Cells were cultured for 96 hours with or without the addition of EpCAMx4-1BB (grey columns) or EpCAMxb12 (striped columns) bispecific antibodies (10 μg / mL) or non-binding control IgG1-b12-FEAL (10 μg / mL; hollow columns) in the presence of anti-CD3 (0.1 μg / mL). The number of CFSE-positive cells was evaluated by flow cytometry as a measure of absolute CD4+ (A) or CD8+ (B) T cell counts, and the division index was calculated. The data shown are the average division index ± SD of repeated measurements obtained from a representative experiment.

[0559] Figure 7 : Enhancement of in vitro PBMC proliferation by EpCAMx4-1BB bispecific antibody in PBMC-tumor cell co-cultures using multiple tumor cell lines.

[0560] EpCAMx4-1BB bispecific antibodies were tested in an in vitro PBMC proliferation assay using T84, DiFi, HPAF-II, NCI-N87, Calu-3 or NCI-H747 tumor cells expressing EpCAM co-cultured with CFSE-labeled PBMCs. In the presence of anti-CD3 (0.1 μg / mL) and a specified concentration of EpCAMx4-1BB or EpCAMxb12 bispecific antibodies or non-binding control IgG1-b12-FEAL, cells were cultured for 96 hours. The number of CFSE-positive cells was evaluated by flow cytometry as a measure of absolute PBMC counts, and the division index was calculated. Data shown are mean division index ± SD of repeated measurements obtained from one representative experiment using (A) PBMC-T84 co-culture, (B) PBMC-DiFi co-culture, (C) PBMC-HPAF-II co-culture, (D) PBMC-NCI-N87 co-culture, (E) PBMC-Calu-3 co-culture, or (F) PBMC-NCI-H747 co-culture.

[0561] Figure 8 . Enhancement of in vitro proliferation of human CD4+ and CD8+ T cells in DiFi tumor cell co-cultures by EpCAMx4-1BB bispecific antibodies with Fc domains containing inert mutations.

[0562] EpCAMx4-1BB bispecific antibodies were tested in an in vitro PBMC proliferation assay using DiFi tumor cells expressing EpCAM co-cultured with CFSE-labeled human PBMCs. In the presence of anti-CD3 (0.1 μg / mL) and specified concentrations of EpCAM-FERLx4-1BB-FEAR (solid diamonds), EpCAM-FEARx4-1BB-FEAL (solid squares), b12-FERLx4-1BB-FEAR (solid triangles in the left half), EpCAM-FERLxb12-FEAR (solid triangles in the right half) bispecific antibodies or non-binding control b12-FERLxb12-FEAR (open triangles), cells were cultured for 96 hours. The number of CFSE-positive (A) CD4+ and (B) CD8+ T cells was evaluated by flow cytometry as a measure of absolute T cell counts, and the division index was calculated. Data shown are nonlinear 4-parameter variable slope fits of mean division index ± SD of replicate measures obtained from a representative experiment using PBMC-DiFi co-cultures.

[0563] Fig. 9 : Enhancement of tumor-infiltrating lymphocyte expansion by EpCAMx4-1BB bispecific antibody in ex vivo patient-derived tumor samples.

[0564] Tumor tissue removed from patients with non-small cell lung cancer was cut into 1 to 2 mm 3 The block was cultured for 14 days in the presence of IL-2 (50U / mL) and 0.2 to 5 μg / mL BsIgG1-CD137-009-HC7LC2-BsIgG1-CD137-009-HC7LC2- or BsIgG1-CD137-009-HC7LC2-FEAL / EpCAM-323-A3-FEAR or only IL-2 (w / o Ab). The IL-2 concentration was gradually reduced to 33U / mL and 15U / mL on the 7th and 10th days, respectively. The absolute cell number after cultivation was determined by flow cytometry. The total TIL, NK cells, CD8+ and CD4+T cell numbers of the culture derived from an exemplary patient in the two patients analyzed are shown. The data from 3 to 4 separate repetitions and the mean value of the repetitions are shown. The error bar shows SD.

[0565] Fig.10 : Antitumor activity of EpCAMx4-1BB bispecific antibody in hEpCAM mice bearing hEpCAM-overexpressing MC38 tumors.

[0566] The mice transgenic for human EpCAM protein (hEpCAM mice) were treated with 5×10 5MC38 tumor cells overexpressing human EpCAM protein (MC38_hEpCAM) were inoculated. When the tumor reached about 30 mm 3 Treatment was started when the mean size of the mice was . On days 12, 17, 21, 24, 28 and 31 after tumor inoculation (vertical dashed lines), mice were treated intraperitoneally with 100 μg BsIgG2amm-EpCAM-323-A3-AALT / m4-1BB-3H3-AAKR or negative control antibody IgG2amm-b12-AAKR. (A) The mean tumor volume of each group is shown, and the error bars show the SEM. The growth curves contain the tumor volume of the last measured mouse sacrificed (last observation carried forward). **, P<0.01; two-way repeated measures ANOVA. (B) Percent survival. *, P<0.05; log-rank (Mantel-Cox) test.

[0567] Fig.11 .Human CD4+ and CD8+ T cell proliferation in PBMC-DiFi tumor cell co-cultures was enhanced by the EpCAMx4-1BB bispecific antibody compared to the combination of bivalent EpCAM-specific and 4-1BB-specific monoclonal antibodies.

[0568] The bispecific antibody bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR was compared with bivalent IgG1-EpCAM-A37-FERL and IgG1-CD137-009-HC7LC2-FEAR (alone or in combination) in an in vitro PBMC proliferation assay using DiFi tumor cells expressing EpCAM co-cultured with human PBMC labeled with CellTrace Violet (CTV). Cells were cultured for 96 hours in the presence of anti-CD3 (0.1 μg / mL; dotted line) and specified concentrations of EpCAMx4-1BB, IgG1-EpCAM-A37-FERL and / or IgG1-CD137-009-HC7LC2-FEAR. CD4+ and CD8+T proliferation were evaluated by flow cytometric analysis of CTV-labeled dilutions. The data shown are the average expansion index ± SD of repeated measurements obtained from one representative experiment.

[0569] Fig.12 .Human CD4+ and CD8+ T cell proliferation in PBMC-DiFi tumor cell co-cultures was enhanced by EpCAMx4-1BB bispecific antibody compared to the combinations of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-HC7LC2-FEAR.

[0570] The bispecific antibody bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR was compared to the combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-HC7LC2-FEAR in an in vitro PBMC proliferation assay using EpCAM-expressing DiFi tumor cells co-cultured with CTV-labeled human PBMCs. Cells were cultured for 96 hours in the presence of anti-CD3 (0.1 μg / mL; dashed line) with the indicated concentrations of bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR or the combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-HC7LC2-FEAR. CD4+ and CD8+ T proliferation was evaluated by flow cytometric analysis of CTV label dilutions. Data shown are the mean percentage of dividing cells ± SD of replicate measurements obtained from one representative experiment.

[0571] Fig.13 .Human CD4+ and CD8+ T cell activation in PBMC-DiFi tumor cell co-cultures was enhanced by EpCAMx4-1BB bispecific antibody compared to the combinations of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-HC7LC2-FEAR.

[0572] The EpCAMx4-1BB bispecific antibody bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR was compared to the combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-HC7LC2-FEAR in an in vitro PBMC proliferation assay using EpCAM-expressing DiFi tumor cells co-cultured with human PBMCs. Cells were cultured for 96 hours in the presence of anti-CD3 (0.1 μg / mL; dashed line) with the indicated concentrations of bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR or the combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-HC7LC2-FEAR. The percentage of CD4+ and CD8+ T cells expressing CD25 (A) or 4-1BB (B) and the geometric mean fluorescence intensity (FI) in the CD25+ population or 4-1BB+ population were determined by flow cytometry. The data shown are the mean ± SD of repeated measurements obtained from one representative experiment.

[0573] Fig.14 .Human CD4+ and CD8+ T cell proliferation in cancer patient-derived PBMC-DiFi tumor cell co-cultures was enhanced by EpCAMx4-1BB bispecific antibody compared to the combinations of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-009-HC7LC2-FEAR.

[0574] EpCAMx4-1BB bispecific antibody bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR was compared to a combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-009-HC7LC2-FEAR in an in vitro proliferation assay using EpCAM-expressing DiFi tumor cells co-cultured with CTV-labeled cancer patient-derived PBMCs. Cells were cultured for 96 hours in the presence of anti-CD3 (0.1 μg / mL; dashed line) with the indicated concentrations of bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR or a combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-009-HC7LC2-FEAR. CD4+ and CD8+ T cell proliferation was assessed by flow cytometric analysis of CTV marker dilutions. Data shown are mean percentage of dividing cells ± SD of replicate measurements obtained from one experiment.

[0575] Fig.15 . EpCAMx4-1BB bispecific antibody enhanced human CD4+ and CD8+ T cell activation in cancer patient-derived PBMC-DiFi tumor cell co-cultures compared to the combinations of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-009-HC7LC2-FEAR.

[0576] EpCAMx4-1BB bispecific antibody bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR was compared to a combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-009-HC7LC2-FEAR in an in vitro proliferation assay using EpCAM-expressing DiFi tumor cells co-cultured with cancer patient-derived PBMCs. Cells were cultured for 96 hours in the presence of anti-CD3 (0.1 μg / mL; dashed line) with the indicated concentrations of bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR or a combination of bsIgG1-EpCAM-A37-FERL / b12-FEAR and bsIgG1-b12-FERL / CD137-009-HC7LC2-FEAR. The percentage of CD4+ and CD8+ T cells expressing CD25 (A) and 4-1BB (B) and the geometric mean fluorescence intensity (FI) in the CD25+ population or 4-1BB+ population were determined by flow cytometry. The data shown are the mean ± SD of repeated measurements obtained from one experiment.

[0577] Fig.16 EpCAMx4-1BB bispecific antibody enhances CD8 + CD107a and GzmB expression on T cells.

[0578] PBMC-derived CD8 T cells expressing CLDN6-specific TCR were cultured in the presence of bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR or control antibody. + T cells were co-cultured with MDA-MB-231_hCLDN6_hEpCAM tumor cells for 2 days. CD8 +CD107a and GzmB expression of T cells. (A) Representative flow cytometry graphs. (B to C) Dose response curves of CD107a (C) and GzmB (D) expression levels. The data shown are the mean and SD of repeated measurements from one of the six donors tested. (D) Normalized CD107a and (E) GzmB expression levels (for each donor, bsIgG1-b12-FERL / b12-FEAR expression levels were set to 1). The combined data from six donors evaluated in two independent experiments are shown. Error bars represent SD. ****, P<0.0001; ***, P<0.001; **, P<0.01; *, P<0.05; Friedman test and Dunn's multiple comparison test. GMFI = geometric mean fluorescence intensity; GzmB = granzyme B; PBMC (peripheral blood mononuclear cell) = peripheral blood mononuclear cells; SD (standard deviation) = standard deviation.

[0579] Fig.17 EpCAMx4-1BB bispecific antibody enhances CD8 + T cell-mediated cytotoxicity against tumor cells.

[0580] PBMC-derived CD8 T cells expressing CLDN6-specific TCR were cultured in the presence of bsIgG1-EpCAM-A37-FERL / CD137-009-HC7LC2-FEAR or control antibody. + T cells were co-cultured with MDA-MB-231_hCLDN6_hEpCAM tumor cells for 5 to 6 days. Cell index values ​​were derived from impedance measurements taken at 2 to 3 hour intervals. (A) shows a cell index curve in a co-culture from a representative donor. Symbols represent the average cell index values ​​of duplicate wells. For better visibility, data from each second impedance measurement (i.e., every 4 to 6 hours) are shown. (B) AUC analysis was performed using cell index data throughout the co-culture period. The AUC for each treatment condition was normalized relative to cultures treated with bsIgG1-ctrl-b12-FERL / b12-FEAR from the same donor. Combined data from all six donors evaluated in two independent experiments are shown. Error bars represent SD. ***, P<0.001; **, P<0.01; *, P<0.05; Friedman test and Dunn multiple comparison test.

[0581] AUC (area under the curve) = area under the curve; PBMC = peripheral blood mononuclear cells; SD = standard deviation.

[0582] Fig.18 Binding of EpCAMx4-1BB bispecific antibodies with different Fc inert mutations (FER / FEA, FEA / FEA, FER / FER) to FcγR

[0583] The binding of EpCAMx4-1BB bispecific antibodies with various combinations of Fc inert mutations (FER / FEA, FEA / FEA, FER / FER) was analyzed by SPR, as well as the binding of monoclonal antibodies IgG1-EpCAM-A37-FERL and IgG1-CD137-009-HC7LC2-FEAR to fixed human recombinant FcγR proteins: FcγRIa, FcγRIIa-H131, FcγRIIa-R131, FcγRIIb, FcγRIIIa-F158 and FcγRIIIa-V158. Antibody IgG1-b12 (wild-type Fc) was included as a positive control for FcγR binding. The relative binding response (in RU (response unit, response unit)) was measured by setting the sensorgram at the moment of SPR analyte injection to 0RU. Each sample analyzed on the active surface was also analyzed on a parallel reference surface for background correction. Shown is the data of a single measurement of an experiment.

[0584] Sequence Description

[0585] Table 1 - Sequences

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592]

[0593]

[0594]

[0595]

[0596]

[0597] DETAILED DESCRIPTION

[0598] Although the present disclosure is further described in more detail below, it should be understood that the present disclosure is not limited to the specific methods, protocols and reagents described herein, as these may vary. It should also be understood that the terms used herein are only for the purpose of describing some specific embodiments and are not intended to limit the scope of the present disclosure, which will be limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art are generally understood.

[0599] Hereinafter, the elements of the present disclosure will be described in more detail. These elements are listed with specific embodiments, however, it should be understood that they can be combined in any manner and in any number to form other embodiments. The embodiments and preferred embodiments of multiple descriptions should not be interpreted as limiting the present disclosure to only the embodiments clearly described. This specification should be understood as supporting and covering the embodiments that will clearly describe the embodiments and any number of disclosed and / or preferred element combinations. In addition, unless the context otherwise indicates, any arrangement and combination of all described elements in the application should be considered to be disclosed by the specification of the application.

[0600] Preferably, the terms used herein are as described in "A multilingual glossary of biotechnological terms: (IUPAC Recommendations)", HGW Leuenberger, B. Nagel and H. Definitions as described in Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995).

[0601] The practice of the present disclosure will employ, unless otherwise indicated, conventional chemistry, biochemistry, cell biology, immunology, and recombinant DNA techniques that are well established in the art (see, e.g.,

[0602] Organikum, Deutscher Verlag der Wissenschaften, Berlin 1990; Streitwieser / Heathcook, "Organische Chemie", VCH, 1990; Beyer / Walter, "Lehrbuchder Organischen Chemie", S.Hirzel Verlag Stuttgart, 1988; Carey / Sundberg, "Organische Chemie", VCH, 1995; March, "Advanced Organic Chemistry", John Wiley & Sons, 1985; Chemie Lexikon, Falbe / Regitz (Hrsg.), Georg Thieme VerlagStuttgart, New York, 1989; Molecular Cloning: A Laboratory Manual, 2nd Edition, J.Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor1989.

[0603] Unless otherwise specified herein or clearly contradictory to the context, all methods described herein may be performed in any suitable order. The use of any and all examples or exemplary language (e.g., "such as") provided herein is intended only to better illustrate the present disclosure and is not intended to limit the scope of the present disclosure otherwise claimed. The language in this specification should not be interpreted as indicating any unclaimed elements necessary for practicing the present disclosure.

[0604] Recitation of ranges of values ​​herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each separate value is incorporated into the specification as if it were individually recited herein.

[0605] Several documents are cited throughout the text of this specification. Each document cited herein (including all patents, patent applications, scientific publications, manufacturer specifications, guidelines, etc.) is hereby incorporated by reference in its entirety, whether above or below. Nothing herein should be construed as an admission that the present invention is not entitled to antedate such disclosures by virtue of prior invention.

[0606] definition

[0607] Definitions applicable to all aspects of the present disclosure are provided below. Unless otherwise indicated, the following terms have the following meanings. Any undefined term has its art-recognized meaning.

[0608] Throughout this specification and the appended claims, unless the context requires otherwise, the words "comprises / comprising" and variations will be understood to imply the inclusion of the stated members, integers or steps or groups of members, integers or steps, but not the exclusion of any other members, integers or steps or groups of members, integers or steps. The term "consisting essentially of" is meant to exclude other members, integers or steps in any substantial sense. The term "comprises / comprising" encompasses the term "consisting essentially of", which in turn encompasses the term "consisting of". Therefore, at each occurrence in this application, the term "comprises / comprising" may be replaced by the term "consisting essentially of" or "consisting of". Similarly, at each occurrence in this application, the term "consisting essentially of" may be replaced by the term "consisting of".

[0609]

[0063] Unless otherwise indicated herein or clearly contradicted by context, unmodified nouns and similar referents used in the context of describing the disclosure (especially in the context of the claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

[0610] As used herein, "and / or" is considered to be specific disclosure that the two specified features or components have or do not have each of the other. For example, "X and / or Y" is considered to be specific disclosure of each of (i) X, (ii) Y, and (iii) X and Y, just as if each were individually listed herein.

[0611] In the context of the present disclosure, the term "about" represents an accuracy interval that a person of ordinary skill in the art will understand to still ensure the technical effect of the feature in question. The term generally represents a deviation from a specified numerical value of ±5%, ±4%, ±3%, ±2%, ±1%, ±0.9%, ±0.8%, ±0.7%, ±0.6%, ±0.5%, ±0.4%, ±0.3%, ±0.2%, ±0.1%, ±0.05%, and for example ±0.01%. As will be understood by a person of ordinary skill, the specific such deviation of the numerical value of a given technical effect will depend on the nature of the technical effect. For example, a natural or biotechnological effect may generally have a larger such deviation than an artificial or modified technical effect.

[0612] The term "binding agent" in the context of the present disclosure refers to any substance that is capable of binding to a desired antigen. In certain embodiments of the present disclosure, the binding agent is an antibody, antibody fragment, or a construct thereof. The binding agent may also comprise a synthetic, modified, or non-naturally occurring portion, particularly a non-peptide portion. Such a portion may, for example, be linked to a desired antigen-binding functional group or region, such as an antibody or antibody fragment. In one embodiment, the binding agent is a synthetic construct comprising an antigen-binding CDR or variable region.

[0613] The term "immunoglobulin" refers to a protein of the immunoglobulin superfamily, preferably to an antigen receptor, such as an antibody or a B cell receptor (B cell receptor, BCR). An immunoglobulin is characterized by a structural domain (i.e., an immunoglobulin domain) having a characteristic immunoglobulin (Ig) fold. The term encompasses membrane-bound immunoglobulins as well as soluble immunoglobulins. Membrane-bound immunoglobulins are also referred to as surface immunoglobulins or membrane immunoglobulins, which are typically part of a BCR. Soluble immunoglobulins are commonly referred to as antibodies.

[0614] The structure of immunoglobulins has been well characterized. See, for example, Fundamental Immunology Ch. 7 (Paul, W., ed., 2 nd ed. Raven Press, NY (1989)). Briefly, immunoglobulins generally consist of several chains, usually two identical heavy chains and two identical light chains, connected by disulfide bonds. These chains are primarily composed of: immunoglobulin domains or immunoglobulin regions, such as V L or VL (variable light chain) domain / region, C L or CL (constant light chain) domain / region, V H or VH (variable heavy chain) domain / region and C H or CH (constant heavy chain) domain / region, C H 1(CH1), C H 2(CH2), C H 3(CH3) and C H4 (CH4). The heavy chain constant region is usually composed of three domains, CH1, CH2 and CH3. The hinge region is the region between the CH1 and CH2 domains of the heavy chain and is highly flexible. The disulfide bond in the hinge region is the part of the interaction between the two heavy chains in the IgG molecule. Each light chain is usually composed of VL and CL. The light chain constant region is usually composed of one domain, CL. The VH and VL regions can be further subdivided into hypervariable regions (or hypervariable regions, which can be in the form of loops with hypervariable sequences and / or structural constraints), also known as complementarity determining regions (CDRs), interspersed with more conservative regions, called framework regions (FRs). Each VH and VL is typically composed of three CDRs and four FRs arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J. Mol. Biol. 196, 901-917 (1987)). Unless otherwise indicated or contradictory to the context, the CDR sequences herein are identified using DomainGapAlign according to the IMGT rules (Lefranc MP., Nucleic Acids Research 1999; 27: 209-212 and Ehrenmann F., Kaas Q. and Lefranc M.-P. Nucleic Acids Res., 38, D301-307 (2010); see also the Internet http address www.imgt.org. However, it should be understood that the present disclosure is not limited to CDR sequences determined solely according to the IMGT rules. Thus, the HCDR1, HCDR2 and HCDR3 sequences of the heavy chain variable region (VH) (e.g., SEQ ID NO: 1 or SEQ ID NO: 11) or the LCDR1, LCDR2 and LCDR3 sequences of the light chain variable region (VL) (e.g., SEQ ID NO: 5 or SEQ ID NO:15) should encompass those CDR sequences determined by any method for determining CDR sequences (e.g., according to the IMGT rules or the Kabat rules). In addition, overlapping sequences representing CDR sequences determined by different methods for determining CDR sequences (e.g., according to the IMGT rules and the Kabat rules) should also be included.

[0615] The table below shows the results of determining CDR sequences related to SEQ ID NO: 1 and SEQ ID NO: 5 or SEQ ID NO: 11 and SEQ ID NO: 15 according to the IMGT rule and the Kabat rule, and also shows the overlap of the determined CDR sequences.

[0616]

[0617] The table below shows the results of determining CDR sequences related to SEQ ID NO: 21 and SEQ ID NO: 22 according to the IMGT rule and the Kabat rule, and also shows the overlap of the determined CDR sequences.

[0618]

[0619] The table below shows the results of determining CDR sequences related to SEQ ID NO: 25 and SEQ ID NO: 26 according to the IMGT rule and the Kabat rule, and also shows the overlap of the determined CDR sequences.

[0620]

[0621] The table below shows the results of determining CDR sequences related to SEQ ID NO: 27 and SEQ ID NO: 28 according to the IMGT rule and the Kabat rule, and also shows the overlap of the determined CDR sequences.

[0622]

[0623] Unless otherwise indicated or contradicted by context, references to amino acid positions in the constant region in this disclosure are according to EU numbering (Edelman et al., Proc Natl Acad Sci USA. 1969 May; 63(1):78-85; Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition. 1991 NIH Publication No. 91-3242).

[0624] There are five types of mammalian immunoglobulin heavy chains, i.e., α, δ, ε, γ and μ, which constitute different types of antibodies, i.e., IgA, IgD, IgE, IgG and IgM. In contrast to the heavy chains of soluble immunoglobulins, the heavy chains of membrane or surface immunoglobulins contain a transmembrane domain and a short cytoplasmic domain at their carboxyl terminus. In mammals, there are two types of light chains, i.e., λ and κ. Immunoglobulin chains contain a variable region and a constant region. The constant region is essentially conserved within different isotypes of immunoglobulins, wherein the variable portion is highly diverse and is responsible for antigen recognition.

[0625] The terms "amino acid" and "amino acid residue" are used interchangeably herein and should not be construed as limiting. Amino acids are organic compounds containing amine (-NH2) and carboxyl (-COOH) functional groups and side chains (R groups) specific to each amino acid. In the context of the present disclosure, amino acids can be classified based on structural and chemical characteristics. Thus, the class of amino acids can be reflected in one or both of the following tables:

[0626] Table 2: Major classifications based on the structure and general chemical characteristics of the R group

[0627]

[0628]

[0629] Table 3: Alternative physical and functional classification of amino acid residues

[0630]

[0631] For the purposes of this disclosure, "variants" of an amino acid sequence (peptide, protein or polypeptide) include amino acid insertion variants, amino acid addition variants, amino acid deletion variants and / or amino acid substitution variants. The term "variant" includes all mutants, splice variants, post-translationally modified variants, conformers, isomers, allelic variants, species variants and species homologs, particularly those occurring in nature. The term "variant" particularly includes fragments of an amino acid sequence.

[0632] Amino acid insertion variants include insertion of a single or two or more amino acids into a specific amino acid sequence. In the case of amino acid sequence variants with insertions, one or more amino acid residues are inserted into a specific site in the amino acid sequence, but random insertion and appropriate screening of the resulting product is also possible.

[0633] Amino acid addition variants include amino-terminal and / or carboxyl-terminal fusions of one or more amino acids (e.g., 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids).

[0634] Amino acid deletion variants are characterized by removing one or more amino acids from the sequence, for example, removing 1, 2, 3, 5, 10, 20, 30, 50 or more amino acids. The deletion can be in any position of the protein. Amino acid deletion variants comprising a deletion of the N-terminal and / or C-terminal of the protein are also referred to as N-terminal and / or C-terminal truncated variants.

[0635] The amino acid substitution variant is characterized in that at least one residue in the sequence is removed, and another residue is inserted in its position. The replacement of one amino acid to another amino acid can be classified as conservative or non-conservative replacement. It is preferred that the modification occurs in the amino acid sequence in a non-conservative position between homologous proteins or peptides and / or replaces the amino acid with other amino acids with similar properties. Preferably, the amino acid changes in peptides and protein variants are conservative amino acid changes, that is, replacements with similar charges or uncharged amino acids. Conservative amino acid changes relate to the replacement of one of the amino acid families associated with its side chain. In the context of the present disclosure, "conservative replacement" is an amino acid replacement with another amino acid having similar structure and / or chemical characteristics, such replacement of an amino acid residue to another amino acid residue of the same type as defined in any one of the above two tables: for example, leucine can be replaced by isoleucine, because both of them are aliphatic, branched hydrophobes. Similarly, aspartic acid can be replaced by glutamic acid, because both of them are small negatively charged residues. Naturally occurring amino acids can generally be divided into four families: acidic amino acids (aspartic acid, glutamic acid), basic amino acids (lysine, arginine, histidine), non-polar amino acids (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan) and uncharged polar amino acids (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine). Phenylalanine, tryptophan and tyrosine are sometimes classified together as aromatic amino acids. In one embodiment, conservative amino acid substitutions include substitutions within the following groups:

[0636] -Glycine, alanine;

[0637] - valine, isoleucine, leucine;

[0638] -Aspartic acid, glutamic acid;

[0639] - Asparagine, glutamine;

[0640] -serine, threonine;

[0641] - lysine, arginine; and

[0642] -Phenylalanine, tyrosine.

[0643] As used herein, the term "amino acid corresponding to the position of..." and similar expressions refer to the amino acid position numbering in the human IgG1 heavy chain. By comparison with human IgG1, the corresponding amino acid positions in other immunoglobulins can be found. Therefore, an amino acid or segment in one sequence that "corresponds" to an amino acid or segment in another sequence is an amino acid or segment that is aligned with another amino acid or segment using a standard sequence alignment program (e.g., ALIGN, ClustalW, or similar programs that are usually set by default) and has at least 50%, at least 80%, at least 90%, or at least 95% identity with the human IgG1 heavy chain. How to align sequences or segments in a sequence and thereby determine the position in the sequence that corresponds to the amino acid position according to the present disclosure is considered to be known in the art.

[0644] The term "antibody" (Ab) in the context of the present disclosure refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or a derivative of any of them, which has the ability to specifically bind to an antigen (particularly an epitope on an antigen) under physiological conditions, preferably with a half-life of a significant period of time, such as at least about 30 minutes, at least about 45 minutes, at least about one hour, at least about two hours, at least about four hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or more days, etc., or any other relevant functionally defined period (e.g., sufficient to induce, promote, enhance, and / or regulate the physiological response associated with the antibody bound to the antigen and / or sufficient to allow the antibody to recruit effector activity). In particular, the term "antibody" refers to a glycoprotein comprising at least two heavy (heavy, H) chains and two light (light, L) chains interconnected by disulfide bonds. The term "antibody" includes monoclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies, and any combination of the foregoing. Each heavy chain comprises a heavy chain variable region (VH) and a heavy chain constant region (CH). Each light chain comprises a light chain variable region (VL) and a light chain constant region (CL). The variable region and constant region are also referred to herein as variable domains and constant domains, respectively. The VH and VL regions can be further subdivided into hypervariable regions called complementary determining regions (CDRs), interspersed with more conservative regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The CDRs of VH are referred to as HCDR1, HCDR2 and HCDR3 (or CDR-H1, CDR-H2 and CDR-H3), and the CDRs of VL are referred to as LCDR1, LCDR2 and LCDR3 (or CDR-L1, CDR-L2 and CDR-L3). The heavy and light chain variable regions comprise binding domains that interact with antigens. The constant region of an antibody comprises a heavy chain constant region (CH) and a light chain constant region (CL), wherein CH can be further subdivided into a constant domain CH1, a hinge region, and constant domains CH2 and CH3 (arranged in the following order from the amino terminus to the carboxyl terminus: CH1, CH2, CH3). The constant region of an antibody can mediate the binding of an immunoglobulin to a host tissue or factor, including various cells of the immune system (e.g., effector cells) and components of the complement system such as C1q. An antibody can be a complete immunoglobulin derived from a natural source or a recombinant source, and can be an immunologically active portion of a complete immunoglobulin. An antibody is typically a tetramer of an immunoglobulin molecule. Antibodies can exist in a variety of forms, including, for example, polyclonal antibodies, monoclonal antibodies, Fv, Fab, and F(ab)2, as well as single-chain antibodies and humanized antibodies.

[0645] The variable regions of the heavy and light chains of the immunoglobulin molecules contain a binding domain that interacts with an antigen. The terms "binding region" and "antigen binding region" are used interchangeably herein and refer to a region that interacts with an antigen and contains both a VH region and a VL region. The antibodies used herein include not only monospecific antibodies, but also multispecific antibodies, which include multiple, such as two or more, such as three or more different antigen binding regions.

[0646] As mentioned above, unless otherwise specified or clearly contradictory from the context, the term antibody herein includes antibody fragments that are antigen binding fragments, i.e., antibody fragments that retain the ability to specifically bind to an antigen. It has been shown that the antigen binding function of an antibody can be performed by fragments of a full-length antibody. Some examples of antigen-binding fragments encompassed within the term "antibody" include (i) Fab' or Fab fragments, which are monovalent fragments consisting of the VL, VH, CL and CH1 domains, or monovalent antibodies as described in WO 2007 / 059782 (Genmab); (ii) F(ab')2 fragments, which are bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragments consisting essentially of the VH and CH1 domains; (iv) Fv fragments consisting essentially of the VL and VH domains of a single arm of an antibody, (v) dAb fragments (Ward et al., Nature 341, 544-546 (1989)), which consist essentially of the VH domain and are also called domain antibodies (Holt et al; Trends Biotechnol. 2003 Nov; 21(11): 484-90); (vi) camelid or nanobody molecules (Revets et al; Expert Opin Biol Ther.2005Jan;5(1):111-24) and (vii) isolated complementary determining regions (CDRs). In addition, although the two domains VL and VH of the Fv fragment are encoded by separate genes, they can be connected by synthetic joints using recombinant methods so that they can become a single protein chain, in which the VL and VH regions are paired to form a monovalent molecule (called a single-chain antibody or single-chain Fv (single chain Fv, scFv), see, for example, Bird et al., Science 242, 423-426 (1988) and Huston et al., PNAS USA 85, 5879-5883 (1988)). Unless otherwise specified or the context clearly indicates, such single-chain antibodies are encompassed within the term antibody. Although such fragments are generally included within the meaning of antibodies, they are collectively and independently unique features of the present disclosure, showing different biological properties and utilities. These and other available antibody fragments in the context of the present disclosure and the bispecific forms of such fragments are further discussed herein. It should also be understood that, unless otherwise indicated, the term antibody also includes polyclonal antibodies, monoclonal antibodies (mAb), antibody-like polypeptides such as chimeric antibodies and humanized antibodies, and antibody fragments (antigen-binding fragments) that retain the ability to specifically bind to an antigen provided by any known technology (such as enzymatic cleavage, peptide synthesis and recombinant technology).

[0647] The antibody thus produced may have any isotype. The term "isotype" as used herein refers to the immunoglobulin class (e.g., IgG (e.g., IgG1, IgG2, IgG3, IgG4), IgD, IgA (e.g., IgA1, IgA2), IgE, IgM, or IgY) encoded by the heavy chain constant region gene. When a specific isotype, such as IgG1, is mentioned herein, the term is not limited to a specific isotype sequence, such as a specific IgG1 sequence, but is used to indicate that the antibody is closer to the isotype, such as IgG1, than other isotypes in sequence. Therefore, for example, the IgG1 antibody disclosed herein can be a sequence variant of a naturally occurring IgG1 antibody, including variants in the constant region.

[0648] IgG1 antibodies can exist in a variety of polymorphic variants called allotypes (reviewed in Jefferis and Lefranc 2009. mAbs Vol 1 Issue 4 1-7), any of which are applicable to some embodiments herein. Common allotype variants in the population are those named by the letters a, f, n, z, or a combination thereof. In any of the embodiments herein, the antibody may comprise a heavy chain Fc region comprising a human IgG Fc region. In other embodiments, the human IgG Fc region comprises human IgG1.

[0649] The term "multispecific antibody" in the context of the present disclosure refers to an antibody having at least two different antigen binding regions defined by different antibody sequences. In some embodiments, the different antigen binding regions bind to different epitopes on the same antigen. However, in some preferred embodiments, the different antigen binding regions bind to different target antigens. In one embodiment, the multispecific antibody is a "bispecific antibody" or "bs". Multispecific antibodies, such as bispecific antibodies, can be in any form, including any bispecific or multispecific antibody form described below.

[0650] For bispecific antibodies, the prefixes BisG1 and bsIgG1 are used interchangeably herein.

[0651] The term "full length" when used in the context of antibodies indicates that the antibody is not a fragment, but rather comprises all domains of a particular isotype that are normally found in nature, e.g., the VH, CH1, CH2, CH3, hinge, VL, and CL domains of an IgG1 antibody.

[0652] The term "human antibody" as used herein is intended to include antibodies with variable regions and framework regions derived from human germline immunoglobulin sequences and antibodies with human immunoglobulin constant domains. Human antibodies disclosed herein may include amino acid residues that are not encoded by human germline immunoglobulin sequences (e.g., mutations, insertions or deletions introduced by random mutagenesis in vitro or site-specific mutagenesis or by somatic mutations in vivo). However, the term "human antibody" as used herein is not intended to include antibodies in which CDR sequences derived from another non-human species (e.g., mouse) germline have been grafted onto human framework sequences.

[0653] The term "chimeric antibody" as used herein refers to an antibody in which the variable region is derived from a non-human species (e.g., from a rodent) and the constant region is derived from a different species such as a human. Chimeric antibodies can be produced by antibody engineering. "Antibody engineering" is a term generally used for antibody modifications of different species, and the method of antibody engineering is well known to technicians. In particular, chimeric antibodies can be produced by using standard DNA techniques as described in Sambrook et al., 1989, Molecular Cloning: Alaboratory Manual, New York: Cold Spring Harbor Laboratory Press, Ch. 15. Therefore, chimeric antibodies can be recombinant antibodies that are genetically modified or enzyme-modified. It is within the knowledge of technicians to produce chimeric antibodies, and therefore, the production of chimeric antibodies can be carried out by other methods other than those described herein. Chimeric monoclonal antibodies for therapeutic applications in humans have been developed to reduce the expected antibody immunogenicity of non-human antibodies (e.g., rodent antibodies). They can generally contain non-human (e.g., mouse or rabbit) variable regions that are specific to the target antigen, as well as human constant antibody heavy and light chain domains. The term "variable region" or "variable domain" used in the context of a chimeric antibody refers to the region comprising the CDRs and framework regions of both the heavy and light chains of an immunoglobulin, as described below.

[0654] The term "humanized antibody" used herein refers to a genetically engineered non-human antibody comprising a human antibody constant domain and a non-human variable domain modified to have a high level of sequence homology with a human variable domain. This can be achieved by grafting six non-human antibody complementary determining regions (CDRs) that form an antigen binding site together to a homologous human acceptor framework region (FR) (see WO 92 / 22653 and EP 0 629 240). In order to completely reconstruct the binding affinity and specificity of the parent antibody, it may be necessary to replace the framework residues from the parent antibody (i.e., non-human antibody) with adult framework regions (reverse mutations). Structural homology modeling can help identify the amino acid residues important for the binding properties of antibodies in the framework region. Therefore, a humanized antibody may include a non-human CDR sequence, optionally including the main human framework region of one or more amino acid reverse mutations for a non-human amino acid sequence, and a completely human constant region. Optionally, other amino acid modifications that are not necessarily reverse mutations may be applied to obtain humanized antibodies with preferred features such as affinity and biochemical properties.

[0655] As used herein, a protein "derived from" another protein (e.g., a parent protein) means that one or more amino acid sequences of the protein are identical or similar to one or more amino acid sequences in another protein or parent protein. For example, in an antibody, binding arm, antigen binding region, or constant region, etc., derived from another antibody or parent antibody, binding arm, antigen binding region, or constant region, one or more amino acid sequences are identical or similar to the amino acid sequences of another antibody or parent antibody, binding arm, antigen binding region, or constant region. Some examples of such one or more amino acid sequences include, but are not limited to, those of VH and VL CDRs and / or one or more or all framework regions, VH, VL, CL, hinge, or CH regions. For example, a humanized antibody may be described herein as "derived from" a non-human parent antibody, which means that at least the VL and VH CDR sequences are identical or similar to the VH and VL CDR sequences of the non-human parent antibody. A chimeric antibody may be described herein as "derived from" a non-human parent antibody, which means that generally the VH and VL sequences may be identical or similar to the VH and VL sequences of the non-human parent antibody. Another example is a binding arm or antigen binding region, which may be described herein as "derived from" a particular parent antibody, meaning that the binding arm or antigen binding region typically comprises the same or similar VH and / or VL CDRs, or VH and / or VL sequences as the binding arm or antigen binding region of the parent antibody. However, as described elsewhere herein, amino acid modifications (e.g., mutations) may be made in the CDRs, constant regions, or elsewhere in the antibody, binding arm, antigen binding region, etc. to introduce desired features. When used in the context of one or more sequences derived from a first protein or parent protein, "similar" amino acid sequences preferably have at least about 50%, such as at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 97%, 98%, or 99% sequence identity.

[0656] Non-human antibodies can be raised in a number of different species (eg, mouse, rabbit, chicken, guinea pig, llama, and goat).

[0657] Monoclonal antibodies can be produced by a variety of techniques, including conventional monoclonal antibody methods, such as the standard somatic cell hybridization technique of Kohler and Milstein, Nature 256:495 (1975). Other techniques for producing monoclonal antibodies can be used, such as viral or oncogenic transformation of B lymphocytes or phage display techniques using antibody gene libraries, and such methods are well known to those skilled in the art.

[0658] Hybridoma production in such non-human species is a very widely recognized procedure. Immunization protocols and techniques for isolating spleen cells from immunized animals / non-human species for fusion are known in the art. Fusion partners (e.g., mouse myeloma cells) and fusion protocols are also known.

[0659] As used herein, the term "Fab arm" or "arm" refers to one heavy chain-light chain pair and is used interchangeably with "half-molecule" herein, unless contradicted by the context.

[0660] The term "binding arm comprising an antigen binding region" means an antibody molecule or fragment comprising an antigen binding region. Thus, a binding arm may comprise, for example, six VH and VL CDR sequences, VH and VL sequences, a Fab or Fab' fragment or a Fab arm.

[0661] When used herein, unless contradictory to the context, the term "Fc region" refers to an antibody region consisting of two Fc sequences of an immunoglobulin heavy chain, wherein the Fc sequence comprises at least a hinge region, a CH2 domain, and a CH3 domain. In one embodiment, the term "Fc region" used herein refers to a region comprising at least a hinge region, a CH2 region, and a CH3 region in the direction from the N-terminus to the C-terminus of an antibody. The Fc region of an antibody can mediate the binding of an immunoglobulin to a host tissue or factor, including various cells of the immune system (e.g., effector cells) and components of the complement system.

[0662] In the context of the present disclosure, the term "induces Fc-mediated effector functions to a lesser extent" as used in relation to an antibody (including a multispecific antibody) means that the antibody induces Fc-mediated effector functions to a lesser extent compared to a human IgG1 antibody comprising (i) the same CDR sequences as the antibody, in particular comprising the same first and second antigen-binding regions, and (ii) two heavy chains comprising the hinge, CH2 and CH3 regions of human IgG1, such functions in particular being selected from the list of IgG Fc receptor (FcgammaR, FcγR) binding, C1q binding, ADCC or CDC.

[0663] Fc-mediated effector function can be measured by binding to FcγRs, binding to C1q, or induction of Fc-mediated cross-linking via FcγRs.

[0664] The term "hinge region" as used herein refers to the hinge region of an immunoglobulin heavy chain. Thus, for example, the hinge region of a human IgG1 antibody corresponds to amino acids 216 to 230 according to EU numbering as described in Kabat (Kabat, EA et al., Sequences of proteins of immunological interest. 5th Edition-US Department of Health and Human Services, NIH publication No. 91-3242, pp662, 680, 689 (1991)). However, the hinge region may also be any other subtype described herein.

[0665] The term "CH1 region" or "CH1 domain" as used herein refers to the CH1 region of an immunoglobulin heavy chain. Thus, for example, the CH1 region of a human IgG1 antibody corresponds to amino acids 118 to 215 according to EU numbering as described in Kabat (supra). However, the CH1 region may also be any other subtype as described herein.

[0666] The term "CH2 region" or "CH2 domain" as used herein refers to the CH2 region of an immunoglobulin heavy chain. Thus, for example, the CH2 region of a human IgG1 antibody corresponds to amino acids 231 to 340 according to EU numbering as described in Kabat (supra). However, the CH2 region may also be any other subtype as described herein.

[0667] The term "CH3 region" or "CH3 domain" as used herein refers to the CH3 region of an immunoglobulin heavy chain. Thus, for example, the CH3 region of a human IgG1 antibody corresponds to amino acids 341 to 447 according to EU numbering as described in Kabat (supra). However, the CH3 region may also be any other subtype as described herein.

[0668] In the context of the present disclosure, the term "monovalent antibody" means that the antibody molecule is able to bind to a single antigen molecule and is therefore not capable of cross-linking antigens.

[0669] An "EpCAM antibody" or "anti-EpCAM antibody" is an antibody as described above, which specifically binds to the antigen EpCAM.

[0670] A "CD137 antibody" or "anti-CD137 antibody" is an antibody as described above, which specifically binds to the antigen CD137.

[0671] “EpCAMxCD137 antibody” or “anti-EpCAMxCD137 antibody” is a bispecific antibody comprising two different antigen binding regions, one of which specifically binds to the antigen EpCAM and the other of which specifically binds to the antigen CD137.

[0672] As used herein, the term "biosimilar" (e.g., a biosimilar of an approved reference product / biologic drug) refers to a biological product that is similar to the reference product based on data from: (a) analytical studies that demonstrate that the biological product is highly similar to the reference product, although there are minor differences in clinically inactive components; (b) animal studies (including toxicity assessments); and / or (c) one or more clinical studies (including assessments of immunogenicity and pharmacokinetics or pharmacodynamics) sufficient to demonstrate safety, purity, and efficacy under one or more appropriate conditions of use for which the reference product is approved and intended for use and for which approval is sought (e.g., there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity, and efficacy of the product). In some embodiments, the biosimilar biological product and the reference product employ the same one or more mechanisms of action for one or more conditions of use specified, recommended, or suggested in the proposed labeling, but only to the extent that one or more mechanisms of action are known for the reference product. In some embodiments, one or more conditions of use specified, recommended, or suggested in the proposed labeling for the biological product have been previously approved for the reference product. In some embodiments, the route of administration, dosage form, and / or strength of the biological product are the same as those of the reference product. A biosimilar may be, for example, a currently known antibody that has the same primary amino acid sequence as a commercially available antibody, but may be prepared in a different cell type or by a different production, purification, or formulation method.

[0673] The term "binds" or "capable of binding" as used herein in the context of binding of an antibody to a predetermined antigen or epitope, typically when determined using bio-layer interferometry (BLI) or, for example, when determined using surface plasmon resonance (SPR) technology in a BIAcore 3000 instrument using an antigen as a ligand and an antibody as an analyte, with a K corresponding to the following: D Affinity binding: about 10 -7 M or less, for example about 10 -8 M or less, for example, about 10 -9 M or smaller, about 10 -10 M or smaller, or about 10 -11 M or even smaller. The antibody has a K corresponding to DThe affinity of the binding site to the predetermined antigen is: the affinity of the binding site to the non-specific antigen (e.g., BSA, casein) other than the predetermined antigen or closely related antigens is: D The amount of higher affinity depends on the K of the antibody. D , so when the antibody's K D When very low (ie, the antibody is highly specific), the affinity for the antigen may be at least 10,000-fold lower than the affinity for a nonspecific antigen.

[0674] The term "k d "(Second -1 ) refers to the dissociation rate constant for a specific antibody-antigen interaction. This value is also called k off value.

[0675] The term "K D ” (M) refers to the dissociation equilibrium constant for a specific antibody-antigen interaction.

[0676] If two antibodies bind to the same antigen and the same epitope, they have the "same specificity". Whether the antibody to be tested recognizes the same epitope as an antigen-binding antibody, i.e., whether the antibodies bind to the same epitope, can be tested by various methods known to those skilled in the art.

[0677] Competition between antibodies can be detected by cross-blocking assay. For example, competitive ELISA assays can be used as cross-blocking assays. For example, the target antigen can be coated on the wells of a microtiter plate, and antigen-binding antibodies and candidate competitive test antibodies can be added. The amount of the antigen-binding antibody bound to the antigen in the well is indirectly related to the binding capacity of the candidate competitive test antibody that competes with the same epitope. Specifically, the greater the affinity of the candidate competitive test antibody to the same epitope, the smaller the amount of the antigen-binding antibody bound to the antigen-coated well. The amount of the antigen-binding antibody bound to the well can be measured by labeling the antibody with a detectable or measurable marker.

[0678] An antibody that competes with another antibody (e.g., an antibody comprising heavy chain and light chain variable regions as described herein) for antigen binding, or an antibody that has specificity for an antigen of another antibody (e.g., an antibody comprising heavy chain and light chain variable regions as described herein) can be an antibody comprising a variant of the heavy and / or light chain variable regions as described herein (e.g., modifications in the CDRs and / or a certain degree of identity as described herein).

[0679] As used herein, "isolated multispecific antibody" is intended to refer to a multispecific antibody that is substantially free of other antibodies with different antigenic specificities (e.g., an isolated bispecific antibody that specifically binds to EpCAM and CD137 that is substantially free of monospecific antibodies that specifically bind to EpCAM or CD137).

[0680] The term "monoclonal antibody" as used herein refers to a preparation of antibody molecules of single molecular composition. A monoclonal antibody composition displays a single binding specificity and affinity for a particular epitope.

[0681] When used herein, the term "heterodimer interaction between the first CH3 region and the second CH3 region" refers to the interaction between the first CH3 region and the second CH3 region in a first CH3 / second CH3 heterodimeric antibody.

[0682] When used herein, the term "homodimer interaction of a first CH3 region with a second CH3 region" refers to the interaction between a first CH3 region and another first CH3 region in a first CH3 / first CH3 homodimeric antibody and the interaction between a second CH3 region and another second CH3 region in a second CH3 / second CH3 homodimeric antibody.

[0683] As used herein, the term "homodimeric antibody" refers to an antibody comprising two first Fab arms or half molecules, wherein the amino acid sequences of said Fab arms or half molecules are identical.

[0684] As used herein, the term "heterodimer antibody" refers to an antibody comprising a first and a second Fab arm or half molecule, wherein the amino acid sequences of the first and second Fab arms or half molecules are different. In particular, the CH3 region or the antigen binding region, or the CH3 region and the antigen binding region of the first Fab arm / half molecule and the second Fab arm / half molecule are different.

[0685] The term "reducing conditions" or "reducing environment" refers to conditions or environments in which a substrate, such as a cysteine ​​residue in an antibody hinge region, is more likely to be reduced than to be oxidized.

[0686] The present disclosure also describes multispecific antibodies (e.g., bispecific antibodies) comprising a functional variant of a VL region, a VH region, or one or more CDRs of the bispecific antibodies of the embodiments. In the case of bispecific antibodies, the functional variants of the VL, VH, or CDRs used still allow each antigen-binding region of the bispecific antibody to retain at least a substantial proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the affinity and / or specificity / selectivity of the parent bispecific antibody, and in some cases, such bispecific antibodies may have greater affinity, selectivity, and / or specificity than the parent bispecific antibody.

[0687] Such functional variants generally retain significant sequence identity with the parent bispecific antibody. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., homology %=# of identical positions / total # of positions × 100), taking into account the number of gaps and the length of each gap, the gap needs to be introduced to achieve the best alignment of the two sequences. The percent identity between two nucleotide or amino acid sequences can be, for example, using the algorithm of E.Meyers and W.Miller, Comput.Appl.Biosci 4, 11-17 (1988), which has been incorporated into the ALIGN program (version 2.0), using PAM120 weight residue table (weight residue table), a gap length penalty of 12, and a gap penalty of 4 to determine. In addition, the percent identity between two amino acid sequences can be determined using Needleman and Wunsch, J.Mol.Biol.48, 444-453 (1970) algorithm.

[0688] In the context of the present disclosure, unless otherwise indicated, the following notations are used to describe mutations: i) amino acid substitutions at a given position are written as, for example, K409R, which means that the lysine at position 409 of the protein is replaced by arginine; and ii) for a particular variant, a specific three-letter code or single-letter code is used, including the codes Xaa and X to represent any amino acid residue. Thus, a replacement of lysine at position 409 with arginine is designated as: K409R, and a replacement of lysine at position 409 with any amino acid residue is designated as K409X. The absence of lysine at position 409 is indicated by K409*.

[0689] Exemplary variants include variants that differ from the VH and / or VL and / or CDR of the parent sequence primarily by conservative substitutions; for example, 12, e.g., 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 substitutions in the variant are conservative amino acid residue replacements.

[0690] In the context of the present disclosure, conservative substitutions can be defined as substitutions within the amino acid classes, as defined in Tables 2 and 3.

[0691] Functional variants of the antibody sequences described herein (e.g., VL or VH regions) or antibody sequences having a certain degree of homology or identity with the antibody sequences described herein (e.g., VL or VH regions) preferably contain modifications or variations in non-CDR sequences, while the CDR sequences preferably remain unchanged.

[0692] The term "EpCAM" as used herein refers to an epithelial cell adhesion molecule, also known as DIAR5, EGP-2, EGP314, EGP40, ESA, HNPCC8, KS1 / 4, KSA, M4S1, MIC18, MK-1, TACSTD1, TROP1, BerEp4, MOC-31, Ber-Ep4. EpCAM is believed to have many different roles and has been shown to play a role in cell adhesion and cancer. In one embodiment, EpCAM is human EpCAM, which has UniProt accession number P16422. The sequence of human EpCAM is also shown in SEQ ID NO: 59. Amino acids at positions 1 to 23 of SEQ ID NO:59 correspond to the signal peptide of human EpCAM; amino acids at positions 24 to 265 of SEQ ID NO:59 correspond to the extracellular domain of human EpCAM; and the remainder of the protein, i.e., amino acids at positions 266 to 288 and 289 to 314 from SEQ ID NO:59 are the transmembrane domain and the cytoplasmic domain, respectively.

[0693] The term "CD137" used herein refers to CD137 (4-1BB), also known as tumor necrosis factor receptor superfamily member 9 (TNFRSF9), which is a receptor for the ligand TNFSF9 / 4-1BBL. CD137 (4-1BB) is considered to be involved in T cell activation. Other synonyms of CD137 include, but are not limited to, 4-1BB ligand receptor, CDw137, T cell antigen 4-1BB homologues, and T cell antigen ILA. In one embodiment, CD137 (4-1BB) is human CD137 (4-1BB), which has UniProt accession number Q07011. The sequence of human CD137 is also shown in SEQ ID NO:37. Amino acids 1 to 23 of SEQ ID NO: 37 correspond to the signal peptide of human CD137; amino acids 24 to 186 of SEQ ID NO: 37 correspond to the extracellular domain of human CD137; and the remainder of the protein, i.e., amino acids 187 to 213 and 214 to 255 from SEQ ID NO: 37 are the transmembrane domain and the cytoplasmic domain, respectively.

[0694] A "treatment cycle" is defined herein as the time period within which the effect of a single dose of a binding agent is increased due to the pharmacodynamics of the binding agent, or in other words, the time period after the administered binding agent is substantially cleared from the subject's body. Multiple small doses within a small time window (e.g., within 2 to 24 hours, such as 2 to 12 hours or on the same day) may be equivalent to a larger single dose.

[0695] In the context of the present invention, the term "treatment" and variations thereof or "therapeutic intervention" refers to the management and care of a subject for the purpose of combating a condition (e.g., a disease or disorder). The term is intended to include the full spectrum of treatments for a given condition suffered by a subject, such as the administration of a therapeutically effective compound to alleviate symptoms or complications, slow the progression of a disease, disorder or condition, alleviate or relieve symptoms and complications, and / or cure or eliminate a disease, disorder or condition, as well as prevent a condition, wherein prevention is understood as the management and care of an individual for the purpose of combating a disease, disorder or disorder, and includes the administration of an active compound to prevent the onset of symptoms or complications. In one embodiment, "treatment" refers to the administration of an effective amount of a therapeutically active binding agent of the present disclosure, such as a therapeutically active antibody, for the purpose of alleviating, ameliorating, preventing, or eradicating (curing) a symptom or disease state.

[0696] Response to treatment, as well as resistance, non-response and / or relapse to treatment with a binding agent of the disclosure may be determined according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST Criteria v1.1).

[0697] "Best overall response" is the best response recorded from the start of treatment until disease progression / recurrence (the minimum measurement recorded since the start of treatment will be used as a reference for PD). Subjects with CR or PR are considered to have an objective response. Subjects with CR, PR or SD are considered to be in disease control. Subjects with NE are considered to be non-responders. The best overall response is the best response recorded from the start of treatment until disease progression / recurrence (the minimum measurement recorded since the start of treatment will be used as a reference for PD). Subjects with CR, PR or SD are considered to be in disease control. Subjects with NE are considered to be non-responders.

[0698] “Duration of response (DOR)” applies only to subjects whose best overall response was confirmed to be CR or PR and is defined as the time from the first documented objective tumor response (CR or PR) to the date of the first PD or death from the underlying cancer.

[0699] Progression-free survival (PFS) was defined as the number of days from day 1 of cycle 1 to the first documented progression or death from any cause.

[0700] “Overall survival (OS)” was defined as the number of days from day 1 of cycle 1 to death from any cause. If the subject was not known to have died, OS was censored at the latest date (on or before the cutoff date) that the subject was known to be alive.

[0701] In the context of this disclosure, the term "treatment regimen" refers to a structured treatment plan designed to improve and maintain health.

[0702] The term "effective amount" or "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the dosage and time period required. The therapeutically effective amount of a binding agent (e.g., an antibody, such as a multispecific antibody or a monoclonal antibody) may vary according to individual factors (e.g., disease state, age, sex, and weight) and the ability of the binding agent to elicit a desired response in an individual. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the binding agent or fragment thereof are outweighed by the therapeutically beneficial effects. In the event that the response in a patient at an initial dose is insufficient, a higher dose may be used (or an effectively higher dose achieved by a different, more localized route of administration). In the event that a patient experiences undesirable side effects at a certain dose, a lower dose may be used (or an effectively lower dose achieved by a different, more localized route of administration).

[0703] As used herein, the term "cancer" includes diseases characterized by abnormally regulated cell growth, proliferation, differentiation, adhesion and / or migration. "Cancer cell" means an abnormal cell that grows by rapid, uncontrolled cell proliferation and continues to grow after the stimulus that initiated new growth has ceased.

[0704] The term "cancer" according to the present disclosure also includes cancer metastasis. "Metastasis" means that cancer cells spread to other parts of the body from their original position. The formation of metastasis is a very complicated process, and depends on the malignant cells to break away from the primary tumor, invade the extracellular matrix, penetrate the endothelial basement membrane to enter the body cavity and blood vessels, and then infiltrate the target organ after being transported by the blood. Eventually, the growth of the new tumor, i.e. secondary tumor or metastatic tumor at the target site depends on angiogenesis. Even after removing the primary tumor, tumor metastasis often occurs, because tumor cells or components may retain and produce metastasis potential. In one embodiment, the term "metastasis" according to the present disclosure relates to "distant metastasis", which relates to the metastasis away from the primary tumor and the local lymph node system.

[0705] As used herein, terms such as "reduce", "inhibit", "interfere" and "negatively regulate" mean the ability to cause an overall decrease in levels, such as about 5% or more, about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 40% or more, about 50% or more, or about 75% or more. The term "inhibit" or similar phrases include complete inhibition or substantially complete inhibition, i.e., reduction to zero or substantially to zero.

[0706] In one embodiment, terms such as "increase" or "enhance" refer to an increase or enhancement of at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 80%, or at least about 100%.

[0707] As used herein, "physiological pH" refers to a pH at or about 7.5.

[0708] "Weight %" as used in the present disclosure refers to weight percent, which is a concentration unit measuring the amount of a substance in grams (g) expressed as a percentage of the total weight of the total composition in grams (g).

[0709] The term "freezing" involves the solidification of a liquid, usually with the removal of heat.

[0710] The term "lyophilization" and its variations refer to the freeze drying of a substance by freezing the substance and then reducing the surrounding pressure (e.g., below 15 Pa, such as below 10 Pa, below 5 Pa or 1 Pa or less) so that the freezing medium in the substance sublimates directly from the solid phase to the gas phase. Therefore, the terms "lyophilizing" and "freeze-drying" are used interchangeably herein.

[0711] The term "recombinant" in the context of the present disclosure means "prepared by genetic engineering." In one embodiment, a "recombinant object" in the context of the present disclosure is not naturally occurring.

[0712] The term "naturally occurring" as used herein refers to the fact that an object can exist in nature. For example, a peptide or nucleic acid that exists in an organism (including a virus) and can be isolated from a natural source and has not been intentionally modified by a person in a laboratory is naturally occurring. The term "existing in nature" means "existing in nature" and includes known objects as well as objects that have not yet been discovered and / or isolated from nature but may be discovered and / or isolated from natural sources in the future.

[0713] According to the present disclosure, the term "peptide" includes oligopeptides and polypeptides, and refers to a substance comprising about two or more, about 3 or more, about 4 or more, about 6 or more, about 8 or more, about 10 or more, about 13 or more, about 16 or more, about 20 or more, and up to about 50, about 100, or about 150 consecutive amino acids connected to each other by peptide bonds. The term "protein" refers to large peptides, particularly peptides having at least about 151 amino acids, but the terms "peptide" and "protein" are often used as synonyms herein.

[0714] A "therapeutic protein" has a positive or beneficial effect on a condition or disease state of a subject when provided to the subject in a therapeutically effective amount. In one embodiment, the therapeutic protein has curative or palliative properties and can be administered to improve, alleviate, mitigate, reverse a disease or disorder, delay the onset of a disease or disorder, or reduce the severity of one or more symptoms of a disease or disorder. Therapeutic proteins can have preventive properties and can be used to delay the onset of a disease or reduce the severity of such a disease or pathological condition. The term "therapeutic protein" includes complete proteins or peptides, and may also refer to therapeutically active fragments thereof. It may also include therapeutically active variants of proteins. Some examples of therapeutically active proteins include, but are not limited to, antigens used for vaccination and immunostimulants (e.g., cytokines).

[0715] The term "portion" refers to a fraction. With respect to a particular structure such as an amino acid sequence or a protein, the term "portion" thereof may refer to a continuous or discontinuous fraction of the structure.

[0716] The terms "part" and "fragment" are used interchangeably herein and refer to a continuous element. For example, a portion of a structure (e.g., an amino acid sequence or a protein) refers to a continuous element of the structure. When used in the context of a composition, the term "portion" means a portion of a composition. For example, a portion of a composition can be any portion of 0.1% to 99.9% (e.g., 0.1%, 0.5%, 1%, 5%, 10%, 50%, 90%, or 99%) of the composition.

[0717] When referring to an amino acid sequence (peptide or protein), "fragment" relates to a part of the amino acid sequence, i.e., refers to a sequence of an amino acid sequence shortened at the N-terminus and / or the C-terminus. A fragment shortened at the C-terminus (N-terminal fragment) can be obtained, for example, by translating a truncated open reading frame lacking the 3' end of the open reading frame. A fragment shortened at the N-terminus (C-terminal fragment) can be obtained, for example, by translating a truncated open reading frame lacking the 5' end of the open reading frame, as long as the truncated open reading frame contains a start codon for initiating translation. A fragment of an amino acid sequence comprises, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% of the amino acid residues from the amino acid sequence. A fragment of an amino acid sequence preferably comprises at least 6, in particular at least 8, at least 12, at least 15, at least 20, at least 30, at least 50 or at least 100 consecutive amino acids from the amino acid sequence.

[0718] According to the present disclosure, a part or fragment of a peptide or protein preferably has at least one functional property of the peptide or protein from which it is derived. Such functional properties include pharmacological activity, interaction with other peptides or proteins, enzymatic activity, interaction with antibodies and selective binding of nucleic acids. For example, a pharmacologically active fragment of a peptide or protein has at least one pharmacological activity of the peptide or protein from which the fragment is derived. A part or fragment of a peptide or protein preferably comprises at least 6, particularly at least 8, at least 10, at least 12, at least 15, at least 20, at least 30 or at least 50 continuous amino acid sequences of a peptide or protein. A part or fragment of a peptide or protein preferably comprises a sequence of up to 8, particularly up to 10, up to 12, up to 15, up to 20, up to 30 or up to 55 continuous amino acids of a peptide or protein.

[0719] "Variant" herein means an amino acid sequence that is different from a parent amino acid sequence due to at least one amino acid modification. The parent amino acid sequence may be a naturally occurring or wild-type (WT) amino acid sequence, or may be a modified form of a wild-type amino acid sequence. Preferably, the variant amino acid sequence has at least one amino acid modification compared to the parent amino acid sequence, for example, 1 to about 20 amino acid modifications compared to the parent, and preferably 1 to about 10 or 1 to about 5 amino acid modifications.

[0720] "Wild type" or "WT" or "native" herein means an amino acid sequence that exists in nature, including allelic variations. A wild type amino acid sequence, peptide or protein has an amino acid sequence that has not been intentionally modified.

[0721] Preferably, the degree of similarity (preferably identity) between a given amino acid sequence and an amino acid sequence that is a variant of the given amino acid sequence will be at least about 60%, 70%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Preferably, the degree of similarity or identity is given for an amino acid region that is at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90% or about 100% of the full length of the reference amino acid sequence. For example, if the reference amino acid sequence consists of 200 amino acids, the degree of similarity or identity is preferably given for at least about 20, at least about 40, at least about 60, at least about 80, at least about 100, at least about 120, at least about 140, at least about 160, at least about 180 or about 200 amino acids (contiguous amino acids in some embodiments). In some embodiments, the degree of similarity or identity is given for the total length of the reference amino acid sequence. Comparisons for determining sequence similarity (preferably sequence identity) can be performed using tools known in the art, preferably using optimal sequence alignment, for example, using Align, using standard settings, preferably EMBOSS::needle, matrix: Blosum62, gap open (Gap Open) 10.0, gap extension (Gap Extend) 0.5.

[0722] "Sequence similarity" refers to the percentage of amino acids that are identical or that represent conservative amino acid substitutions. "Sequence identity" between two amino acid sequences refers to the percentage of amino acids that are identical between the sequences. "Sequence identity" between two nucleic acid sequences refers to the percentage of nucleotides that are identical between the sequences.

[0723] The terms "% identical" and "% identity" or similar terms are particularly intended to refer to the percentage of nucleotides or amino acids that are identical in an optimal alignment between the sequences to be compared. The percentage is purely statistical, and the differences between the two sequences may be, but are not necessarily, randomly distributed over the entire length of the sequences to be compared. The comparison of two sequences is usually performed by comparing the sequences after optimal alignment over a segment or "comparison window" to determine local regions of corresponding sequences. Optimal alignment for comparison can be performed manually or with the aid of the local homology algorithm of Smith and Waterman, 1981, Ads App. Math. 2, 482, with the aid of the local homology algorithm of Needleman and Wunsch, 1970, J. Mol. Biol. 48, 443, with the aid of the similarity search algorithm of Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444, or with the aid of computer programs that use such algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In some embodiments, the percentage identity of two sequences is determined using the BLASTN or BLASTP algorithm available on the National Center for Biotechnology Information (NCBI) website (e.g., at blast.ncbi.nlm.nih.gov / Blast.cgi). In some embodiments, the algorithm parameters used by the BLASTN algorithm on the NCBI website include: (i) the expected threshold is set to 10; (ii) the word length is set to 28; (iii) the maximum match within the query range is set to 0; (iv) the match / mismatch score is set to 1, -2; (v) the gap cost is set to linear; and (vi) a filter for low complexity regions being used. In some embodiments, the algorithm parameters used by the BLASTP algorithm on the NCBI website include: (i) the expected threshold is set to 10; (ii) the word length is set to 3; (iii) the maximum match within the query range is set to 0; (iv) the matrix is ​​set to BLOSUM62; (v) the gap cost is set to existence: 11, extension: 1; and (vi) the condition composition score matrix adjustment.

[0724] The percent identity is calculated by determining the number of identical positions in the sequences being compared, dividing that number by the number of positions being compared (eg, the number of positions in the reference sequence), and multiplying the result by 100.

[0725] In some embodiments, the degree of similarity or identity is given for a region that is at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or about 100% of the full length of the reference sequence. For example, if the reference amino acid sequence consists of 200 amino acid residues, the degree of identity is given for at least about 100, at least about 120, at least about 140, at least about 160, at least about 180, or about 200 amino acid residues (in some embodiments, continuous amino acid residues). In some embodiments, the degree of similarity or identity is given for the full length of the reference sequence.

[0726] According to the present disclosure, homologous amino acid sequences show at least 40%, particularly at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, and preferably at least 95%, at least 98% or at least 99% identity of the amino acid residues.

[0727] The amino acid sequence variants described herein can be easily prepared by a skilled person, for example, by recombinant DNA manipulation. For example, manipulations for preparing DNA sequences of peptides or proteins with substitutions, additions, insertions or deletions are described in detail in Sambrook et al. (1989). In addition, the peptides and amino acid variants described herein can be easily prepared by means of known peptide synthesis techniques, for example, such as by solid phase synthesis and similar methods.

[0728] In one embodiment, a fragment or variant of an amino acid sequence (peptide or protein) is preferably a "functional fragment" or "functional variant". The term "functional fragment" or "functional variant" of an amino acid sequence relates to any fragment or variant that exhibits one or more functional properties that are identical or similar to one or more functional properties of the amino acid sequence from which the fragment or variant is derived (i.e., it is functionally equivalent). With respect to a binding agent, a specific function is one or more binding activities exhibited by the amino acid sequence from which the fragment or variant is derived. The term "functional fragment" or "functional variant" as used herein refers in particular to a variant molecule or sequence that comprises an amino acid sequence in which one or more amino acids have been changed compared to the amino acid sequence of a parent molecule or sequence and that is still capable of achieving one or more functions of the parent molecule or sequence (e.g., binding to a target antigen). In one embodiment, the modification in the amino acid sequence of a parent molecule or sequence does not significantly affect or change the characteristics of the molecule or sequence. In some different embodiments, the function of the functional fragment or functional variant can be reduced but still significantly present, for example, the binding of the functional variant can be at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the parent molecule or sequence. However, in other embodiments, the function of the functional fragment or functional variant can be enhanced compared to the parent molecule or sequence.

[0729] An amino acid sequence (peptide, protein or polypeptide) "derived from" a specified amino acid sequence (peptide, protein or polypeptide) refers to the source of the first amino acid sequence. Preferably, the amino acid sequence derived from a specific amino acid sequence has an amino acid sequence that is identical, substantially identical or homologous to the specific sequence or a fragment thereof. The amino acid sequence derived from a specific amino acid sequence may be a variant of the specific sequence or a fragment thereof. For example, one of ordinary skill in the art will appreciate that the binding agents used herein may be altered so that their sequence is different from the naturally occurring or native sequence from which they are derived while retaining the desired activity of the native sequence.

[0730] "Isolated" means changed or separated from the natural state. For example, a nucleic acid or peptide naturally present in a living animal is not "isolated", but the same nucleic acid or peptide partially or completely separated from coexisting materials in its natural state is "isolated". An isolated nucleic acid or protein may exist in a substantially purified form, or may exist in a non-natural environment, such as, for example, a host cell. In one embodiment, the binding agents (e.g., antibodies) described herein are isolated. "Isolated binding agent" as used herein is intended to refer to a binding agent that is substantially free of other binding agents with different antigenic specificities. In one embodiment, an isolated bispecific binding agent that specifically binds to EpCAM and CD137 is substantially free of monospecific antibodies that specifically bind to EpCAM or CD137. In a preferred embodiment, the binding agent used in the present disclosure is in a substantially purified form.

[0731] The term "genetic modification" or simply "modification" includes transfecting cells with nucleic acids. The term "transfection" involves the introduction of nucleic acids, particularly RNA, into cells. For the purposes of the present disclosure, the term "transfection" also includes the introduction of nucleic acids into cells or the uptake of nucleic acids by such cells, wherein the cells may be present in a subject, such as a patient. Therefore, according to the present disclosure, cells for transfection of nucleic acids described herein may be present in vitro or in vivo, for example, the cells may form a part of an organ, tissue and / or organism of a patient. According to the present disclosure, transfection may be transient or stable. For some applications of transfection, it is sufficient when the transfected genetic material is only transiently expressed. RNA may be transfected into cells to transiently express the protein it encodes. Since the nucleic acids introduced during the transfection process are generally not integrated into the nuclear genome, the exogenous nucleic acids will be diluted or degraded by mitosis. Cells that allow free amplification of nucleic acids greatly reduce the dilution rate. If it is desired that the transfected nucleic acids are actually retained in the genome of the cell and its daughter cells, stable transfection must occur. Such stable transfection can be achieved by using a virus-based system or a transposon-based system for transfection. Generally speaking, nucleic acid encoding an antigen is transiently transfected into cells. RNA can be transfected into cells to transiently express its encoded protein.

[0732] According to the present disclosure, the analog of a peptide or protein is a modified form of the peptide or protein from which it is derived, and has at least one functional property of the peptide or protein. For example, a pharmacologically active analog of a peptide or protein has at least one pharmacological activity of the peptide or protein from which the analog is derived. Such modification includes any chemical modification, and includes single or multiple replacements, deletions and / or additions of any molecule such as carbohydrates, lipids and / or proteins or peptides associated with a protein or peptide. In one embodiment, the "analog" of a protein or peptide includes those modified forms obtained by glycosylation, acetylation, phosphorylation, amidation, palmitoylation, myristoylation, isoprenylation, lipidation, alkylation, derivatization, introduction of protection / blocking groups, proteolytic cleavage or binding to antibodies or other cellular ligands. The term "analog" also extends to all functional chemical equivalents of the protein and peptide.

[0733] "Activation" or "stimulation" used herein refers to the state of immune effector cells (e.g., T cells) that have been sufficiently stimulated to induce detectable cell proliferation. Activation can also be associated with the initiation of signal transduction pathways, induced cytokine production, and detectable effector functions. The term "activated immune effector cells" refers especially to immune effector cells that are undergoing cell division.

[0734] The term "sensitization" refers to the process in which an immune effector cell (eg, a T cell) first comes into contact with its specific antigen and results in differentiation into an effector cell (eg, an effector T cell).

[0735] The term "clonal expansion" or "amplification" refers to a process in which a particular entity multiplies. In the context of the present disclosure, the term is preferably used in the context of an immune response in which immune effector cells are stimulated by an antigen, proliferate, and specific immune effector cells that recognize the antigen expand. Preferably, clonal expansion results in differentiation of immune effector cells.

[0736] "Antigen" according to the present disclosure encompasses any substance or molecular structure that can bind to an antibody or T cell receptor. The presence of an antigen in an organism can cause an immune response. Therefore, "antigen" encompasses any substance to which an immune response or immune mechanism is directed. This also includes situations in which an antigen is processed into antigenic peptides, and the immune response or immune mechanism is directed to one or more antigenic peptides, particularly if presented in the context of an MHC molecule. In particular, "antigen" relates to any substance, preferably a peptide or protein, that specifically reacts with an antibody or T lymphocyte (T cell). According to the present disclosure, the term "antigen" includes any molecule comprising at least one epitope (e.g., a T cell epitope). Preferably, an antigen in the context of the present disclosure is a molecule that induces an immune response, optionally after processing, and the immune response is preferably specifically directed to the antigen (including cells expressing the antigen). In one embodiment, the antigen is a disease-associated antigen, such as a tumor antigen, a viral antigen, or a bacterial antigen, or an epitope derived from such an antigen.

[0737] The term "epitope" refers to an antigenic determinant in a molecule (e.g., an antigen), that is, a portion or fragment of a molecule that is recognized by the immune system, such as by an antibody T cell or B cell, particularly when presented in the context of an MHC molecule. In one embodiment, an "epitope" means a protein determinant that can specifically bind to an antibody. An epitope is usually composed of surface groups (e.g., amino acids or sugar side chains) of a molecule, and usually has specific three-dimensional structural features and specific charge characteristics. The difference between a conformational epitope and a non-conformational epitope is that, in the presence of a denaturing solvent, the binding to the former is lost, while the binding to the latter is not lost. An epitope may include amino acid residues that are directly involved in binding and other amino acid residues that are not directly involved in binding, such as amino acid residues that are effectively blocked or covered by a specific antigen-binding peptide (in other words, the amino acid residues are within the footprint of the specific antigen-binding peptide).

[0738] The epitope of a protein preferably comprises a continuous or discontinuous portion of the protein and is preferably about 5 to about 100 amino acids in length, preferably about 5 to about 50, more preferably about 8 to about 30, most preferably about 10 to about 25 amino acids in length, for example, the length of the epitope may preferably be 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 amino acids. In one embodiment, the epitope in the context of the present disclosure is a T cell epitope.

[0739] The terms "optional" or "optionally" as used herein mean that the subsequently described event, condition or circumstance may or may not occur, and that the description includes instances where said event, condition or circumstance occurs and instances where said event, condition or circumstance does not occur.

[0740] As used herein, the terms "linked", "fused" or "fusion / fusion" are used interchangeably. These terms refer to the joining of two or more elements or components or domains together.

[0741] The term "disease" (also referred to herein as "disorder") refers to an abnormal condition that affects an individual's body. Disease is generally interpreted as a medical condition associated with specific symptoms and signs. Disease can be caused by factors that are initially from an external source, such as an infectious disease, or disease can be caused by an internal dysfunction, such as an autoimmune disease. In people, "disease" is generally more widely used to refer to any condition that causes pain, dysfunction, suffering, social problems or death in a sick individual or similar problems of those in contact with the individual. Broadly speaking, disease sometimes includes injury, disability, disorder, syndrome, infection, isolated symptoms, abnormal behavior, and atypical changes in structure and function, while in other cases and for other purposes, these can be considered to be distinguishable categories. Diseases usually affect individuals not only physically but also emotionally, because infection and experience with many diseases can change an individual's view of life and the character of the individual.

[0742] The term "therapeutic treatment" refers to any treatment that improves the health status of an individual and / or prolongs (improves) the life span of an individual. The treatment can eliminate the disease in an individual, prevent or slow the occurrence of the disease in an individual, inhibit or slow the occurrence of the disease in an individual, reduce the frequency or severity of symptoms in an individual, and / or reduce recurrence in an individual currently suffering from or previously suffering from the disease.

[0743] The term "prophylactic treatment" or "preventative treatment" relates to any treatment intended to prevent a disease from occurring in an individual. The terms "prophylactic treatment" or "preventative treatment" are used interchangeably herein. Similarly, in the context of disease progression (e.g., progression of a tumor or cancer), the term "method for preventing" relates to any method intended to prevent disease progression in an individual.

[0744] The terms "individual" and "subject" are used interchangeably herein. They refer to humans or other mammals (e.g., mice, rats, rabbits, dogs, cats, cattle, pigs, sheep, horses, or primates) or any other non-mammals (including birds (chickens), fish, or any other animal species) that may suffer from a disease or condition (e.g., cancer) or are susceptible to a disease or condition (e.g., cancer). Unless otherwise indicated, the terms "individual" and "subject" do not indicate a specific age, and therefore encompass adults, the elderly, children, and newborns. In some embodiments of the present disclosure, an "individual" or "subject" is a "patient".

[0745] The term "patient" refers to an individual or subject being treated, particularly an individual or subject who is ill.

[0746] As used herein, the term "polynucleotide" or "nucleic acid" is intended to include DNA and RNA, such as genomic DNA, cDNA, mRNA, recombinantly produced and chemically synthesized molecules. Nucleic acids can be single-stranded or double-stranded. RNA includes in vitro transcribed RNA (IVT RNA) or synthetic RNA.

[0747] Nucleic acid can be contained in a vector. The term "vector" used herein includes any vector known to the technician, including a plasmid vector, a cosmid vector, a phage vector (e.g., lambda phage), a viral vector (e.g., a retrovirus, an adenovirus or a baculovirus vector), or an artificial chromosome vector (e.g., a bacterial artificial chromosome (BAC), a yeast artificial chromosome (YAC) or a P1 artificial chromosome (PAC)). The vector includes an expression vector and a cloning vector. The expression vector includes a plasmid and a viral vector and generally includes a desired coding sequence and a suitable DNA sequence necessary for expressing an operably connected coding sequence in a specific host organism (e.g., bacteria, yeast, plants, insects or mammals) or in an in vitro expression system. Cloning vectors are generally used to transform and amplify specific desired DNA fragments, and may lack the functional sequences required for expressing the desired DNA fragments.

[0748] In one embodiment of the present disclosure, the nucleic acid is expressed in the cells of the subject being treated to provide the encoded peptide or protein. In one embodiment, the nucleic acid is transiently expressed in the cells of the subject. Thus, in one embodiment, the nucleic acid is not integrated into the genome of the cell. In one embodiment, the nucleic acid is RNA, preferably in vitro transcribed RNA.

[0749] The nucleic acids described herein may be recombinant and / or isolated molecules.

[0750] In the present disclosure, the term "RNA" refers to a nucleic acid molecule comprising ribonucleotide residues. In some preferred embodiments, RNA comprises all or most of the ribonucleotide residues. "Ribonucleotide" used herein refers to a nucleotide having a hydroxyl group at the 2' position of the β-D-ribofuranosyl group. RNA encompasses but is not limited to double-stranded RNA, single-stranded RNA, isolated RNA (e.g., partially purified RNA), substantially pure RNA, synthetic RNA, recombinantly produced RNA, and modified RNA that is different from naturally occurring RNA by adding, deleting, replacing and / or changing one or more nucleotides. Such a change may refer to adding a non-nucleotide substance to an internal RNA nucleotide or the end of the RNA. It is also contemplated herein that the nucleotides in the RNA may be non-standard nucleotides, such as chemically synthesized nucleotides or deoxynucleotides. For the present disclosure, these altered RNAs are considered to be analogs of naturally occurring RNA.

[0751] In certain embodiments of the present disclosure, RNA is messenger RNA (mRNA), which relates to RNA transcripts encoding peptides or proteins. As recognized in the art, mRNA generally comprises a 5' untranslated region (5'untranslated region, 5'-UTR), a peptide coding region, and a 3' untranslated region (3'untranslated region, 3'-UTR). In some embodiments, RNA is produced by in vitro transcription or chemical synthesis. In one embodiment, mRNA is produced by in vitro transcription using a DNA template, wherein DNA refers to a nucleic acid comprising deoxyribonucleotides.

[0752] In one embodiment, the RNA is an in vitro transcribed RNA (IVT-RNA) and can be obtained by in vitro transcription of a suitable DNA template. The promoter used to control transcription can be any promoter of any RNA polymerase. The DNA template for in vitro transcription can be obtained by cloning nucleic acid, particularly cDNA, and introducing it into a suitable vector for in vitro transcription. cDNA can be obtained by reverse transcription of RNA.

[0753] In one embodiment, the RNA described herein may have modified nucleosides. In some embodiments, the RNA comprises a modified nucleoside replacing at least one (eg, each) uridine.

[0754] In some embodiments, the modified nucleosides are independently selected from pseudouridine (ψ), N1-methyl-pseudouridine (m1ψ), and 5-methyl-uridine (m5U).

[0755] In some embodiments, the modified nucleosides replacing one or more uridines in the RNA may be any one or more of the following: 3-methyl-uridine (m3 U), 5-methoxy-uridine (mo 5 U), 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s 2 U), 4-thio-uridine (s 4 U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho 5 U), 5-aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), uridine 5-hydroxyacetic acid (cmo 5 U), uridine 5-hydroxyacetate (mcmo 5 U), 5-carboxymethyl-uridine (cm 5 U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine (chm 5 U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm 5 U), 5-methoxycarbonylmethyl-uridine (mcm 5 U), 5-methoxycarbonylmethyl-2-thio-uridine (mcm 5 s 2 U), 5-aminomethyl-2-thio-uridine (nm 5 s 2 U), 5-methylaminomethyl-uridine (mnm 5 U), 1-ethyl-pseudouridine, 5-methylaminomethyl-2-thio-uridine (mnm 5 s 2 U), 5-methylaminomethyl-2-seleno-uridine (mnm 5 s 2 U), 5-carbamoylmethyl-uridine (ncm 5 U), 5-carboxymethylaminomethyl-uridine (cmnm 5 U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm 5 s 2 U), 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-taurine methyl-uridine (τm 5 U), 1-taurine methyl-pseudouridine, 5-taurine methyl-2-thio-uridine (τm5s2U), 1-taurine methyl-4-thio-pseudouridine), 5-methyl-2-thio-uridine (m 5 s 2 U), 1-methyl-4-thio-pseudouridine (m 1 s 4 ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m 3ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine (m 5 D), 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine (acp 3 U), 1-methyl-3-(3-amino-3-carboxypropyl) pseudouridine (acp 3 ψ), 5-(isopentenylaminomethyl)uridine (inm 5 U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm 5 s 2 U), α-thio-uridine, 2'-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m 5 Um), 2'-O-methyl-pseudouridine (ψm), 2-thio-2'-O-methyl-uridine (s 2 Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm 5 Um), 5-carbamoylmethyl-2'-O-methyl-uridine (ncm 5 Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm 5 Um), 3,2'-O-dimethyl-uridine (m 3 Um), 5-(isopentenylaminomethyl)-2'-O-methyl-uridine (inm 5 Um), 1-thio-uridine, deoxythymidine, 2'-F-arabino-uridine, 2'-F-uridine, 2'-OH-arabino-uridine, 5-(2-methoxycarbonylvinyl)uridine, 5-[3-(1-E-propenylamino)uridine, or any other modified uridine known in the art.

[0756] In some embodiments, the RNA according to the present disclosure comprises a 5'-cap. In one embodiment, the RNA of the present disclosure does not have an uncapped 5'-triphosphate. In one embodiment, the RNA may be modified by a 5'-cap analog. The term "5'-cap" refers to a structure found at the 5'-end of an mRNA molecule, and is typically composed of a guanosine nucleotide linked to the mRNA via a 5' to 5' triphosphate linkage. In one embodiment, the guanosine is methylated at position 7. Providing an RNA with a 5'-cap or a 5'-cap analog can be achieved by in vitro transcription, wherein the 5'-cap is co-transcriptionally expressed into the RNA chain, or a capping enzyme can be used to post-transcriptionally link the RNA.

[0757] In some embodiments, the RNA comprises cap 0, cap 1, or cap 2. According to the present disclosure, the term "cap 0" means the structure "cap 1". 7 GpppN", wherein N is any nucleoside with an OH moiety at the 2' position. According to the present disclosure, the term "cap 1" means the structure "m 7 GpppNm", wherein Nm is any nucleoside with an OCH3 moiety at the 2' position. According to the present disclosure, the term "cap 2" means the structure "m 7 GpppNmNm", wherein each Nm is independently any nucleoside with an OCH3 moiety at the 2' position.

[0758] In some embodiments, the RNA comprises a 5'-cap structure selected from: m2 7,2’O G(5')ppSp(5')G (especially its D1 diastereomer), m2 7,3’O G(5')ppp(5')G, and m2 7,3’-O Gppp(m1 2’-O )ApG.

[0759] In some embodiments, the RNA according to the present disclosure comprises a 5'-UTR and / or a 3'-UTR. The term "untranslated region" or "UTR" refers to a region in a DNA molecule that is transcribed but not translated into an amino acid sequence, or to a corresponding region in an RNA molecule (e.g., an mRNA molecule). An untranslated region (UTR) may be present at the 5' (upstream) (5'-UTR) and / or the 3' (downstream) (3'-UTR) of an open reading frame. The 5'-UTR, if present, is located at the 5' end, upstream of the start codon of the protein coding region. The 5'-UTR is located downstream of the 5'-cap (if present), for example, directly adjacent to the 5'-cap. The 3'-UTR, if present, is located at the 3' end, downstream of the stop codon of the protein coding region, but the term "3'-UTR" preferably does not include a poly (A) sequence. Therefore, the 3'-UTR is located upstream of the poly (A) sequence (if present), for example, directly adjacent to the poly (A) sequence.

[0760] In some embodiments, the RNA according to the present disclosure comprises a 3'-poly (A) sequence. The term "poly (A) sequence" or "poly-A tail" as used herein refers to an uninterrupted or discontinuous sequence of adenylic acid residues, which is generally located at the 3' end of an RNA molecule. The poly (A) sequence is known to those skilled in the art and may be immediately adjacent to the 3'UTR in the RNA described herein. The poly (A) sequence may be of any length. In some embodiments, the poly (A) sequence comprises or consists of at least 20, at least 30, at least 40, at least 80 or at least 100 and at most 500, at most 400, at most 300, at most 200 or at most 150 nucleotides, and in particular about 110 nucleotides. In some embodiments, the poly (A) sequence consists only of A nucleotides. In some embodiments, the poly(A) sequence consists essentially of A nucleotides but is interrupted by a random sequence of four nucleotides (A, C, G and U), as disclosed in WO 2016 / 005324 A1, which is incorporated herein by reference. Such a random sequence may be 5 to 50, 10 to 30 or 10 to 20 nucleotides in length. The poly(A) box exhibits continuous proliferation of plasmid DNA in E. coli at the DNA level and is still associated with beneficial properties for supporting RNA stability and translation efficiency at the RNA level, the poly(A) box being present in a DNA coding strand that consists essentially of dA nucleotides but is interrupted by a random sequence of four nucleotides (dA, dC, dG, dT) having an even distribution and a length of, for example, 5 to 50 nucleotides. In some embodiments, no nucleotides other than A nucleotides are flanked by the poly(A) sequence at its 3' end, i.e., the poly(A) sequence is not masked or followed by a nucleotide other than A at its 3' end.

[0761] In the context of the present disclosure, the term "transcription" refers to the process in which the genetic code in a DNA sequence is transcribed into RNA. Subsequently, the RNA can be translated into a peptide or protein.

[0762] "Encoding" refers to the inherent property of a specific nucleotide sequence in a polynucleotide (e.g., a gene, cDNA, or mRNA) to serve as a template for the synthesis of other polymers and macromolecules in biological processes, which have a defined nucleotide sequence (i.e., rRNA, tRNA, and mRNA) or a defined amino acid sequence and the biological properties resulting therefrom. Thus, if transcription and translation of the mRNA corresponding to the gene produces the protein in a cell or other biological system, the gene encodes the protein. Both the coding strand (whose nucleotide sequence is identical to the mRNA sequence and is generally provided in a sequence listing) and the non-coding strand (which serves as a transcription template for a gene or cDNA) can be said to encode a protein or other product of the gene or cDNA. Similarly, if translation of an RNA (e.g., an mRNA) produces the protein in a cell or other biological system, the RNA encodes the protein.

[0763] The RNA can be naked or packaged, for example prepared in particles such as protein and / or lipid particles (eg, lipid nanoparticles).

[0764] As used herein, "endogenous" refers to any substance that originates from or is produced within an organism, cell, tissue or system.

[0765] As used herein, the term "exogenous" refers to any substance introduced or generated from outside an organism, cell, tissue or system.

[0766] The term "expression" as used herein is defined as the transcription and / or translation of a specific nucleotide sequence.

[0767] The Fc region may have lysine at its C-terminus. The source of the lysine is a naturally occurring sequence present in humans, and these Fc regions are derived from the sequence. During cell culture to produce recombinant antibodies, the terminal lysine can be cut off by proteolysis of endogenous carboxypeptidases, producing a constant region with the same sequence but lacking C-terminal lysine. For the purpose of preparing antibodies, the DNA encoding the terminal lysine can be omitted from the sequence so that antibodies without lysine are produced. The antibodies produced by nucleic acid sequences encoding or not encoding the terminal lysine are substantially the same in sequence and function, because when, for example, antibodies produced in a CHO-based production system are used, the degree of processing of the terminal lysine is usually high (Dick, LW et al. Biotechnol. Bioeng. 2008; 100: 1132-1143). Therefore, it should be understood that proteins (such as antibodies) according to the present invention can be produced in the case of encoding or having or not encoding or having a terminal lysine.

[0768] Some aspects and embodiments of the present disclosure

[0769] Binders that bind to EpCAM and CD137

[0770] In a first aspect, the present disclosure provides a binding agent comprising a first binding region that binds to EpCAM and a second binding region that binds to CD137.

[0771] The binding agents disclosed herein can be antibodies of any isotype in principle. The selection of isotype is usually guided by the desired Fc-mediated effector function (e.g., ADCC induction), or by the need for antibodies lacking Fc-mediated effector function ("inert" antibodies). Exemplary isotypes are IgG1, IgG2, IgG3, and IgG4. Any of the human light chain constant regions (κ or λ) can be used. The effector function of the antibodies described herein can be changed for a variety of therapeutic uses by isotype conversion into, for example, IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibodies. In one embodiment, the two heavy chains of the antibodies described herein are all IgG1 isotypes, such as IgG1, κ. Optionally, the heavy chain can be modified in the hinge region and / or CH3 region, as described elsewhere herein.

[0772] Preferably, each antigen binding region comprises a heavy chain variable region (VH) and a light chain variable region (VL), and wherein each of the variable regions comprises three CDR sequences, namely CDR1, CDR2 and CDR3, and four framework sequences, namely FR1, FR2, FR3 and FR4. In addition, preferably, the antibody comprises two heavy chain constant regions (CH) and two light chain constant regions (CL).

[0773] In one embodiment, the binding agent is a full length antibody, such as a full length IgG1 antibody.For example, in one embodiment, the binding agent (eg, a bispecific antibody) comprises two half molecules, each of which comprises an antigen binding region.

[0774] Many different forms of bispecific antibodies are known in the art and are reviewed by Kontermann; Drug Discov Today, 2015 Jul; 20(7): 838-47 and MAbs, 2012 Mar-Apr; 4(2): 182-97. All of these forms are encompassed herein. The bispecific antibodies according to the present disclosure are not limited to any particular bispecific form or method of generating the same.

[0775] Some examples of bispecific antibody molecules that can be used in the present disclosure include (i) single antibodies, which have two arms containing different antigen binding regions; (ii) single-chain antibodies, which have specificity for two different epitopes, such as two scFvs connected in series by an additional peptide linker; (iii) dual-variable-domain antibodies (DVD-Ig), in which each light chain and heavy chain contains two variable domains connected in series by a short peptide bond (Wu et al., Generation and Characterization of a Dual Variable Domain Immunoglobulin (DVD-Ig)). TM ) Molecule, in Antibody Engineering, Springer Berlin Heidelberg (2010)); (iv) chemically linked bispecific (Fab')2 fragments; (v) Tandab, which is a fusion of two single-chain diabodies, resulting in a tetravalent bispecific antibody with two binding sites for each target antigen; (vi) flexibody, which is a combination of scFv and diabody, resulting in a multivalent molecule; (vii) so-called "dock and lock" molecules, which are based on the "dimerization and docking domain" in protein kinase A, and when applied to Fab, can produce a trivalent bispecific binding protein consisting of two identical Fab fragments linked to different Fab fragments; (viii) so-called scorpion molecules, which comprise, for example, two scFvs fused to the two ends of a human Fab arm; and (ix) diabodies.

[0776] In one embodiment, the binding agent described herein is a diabody or a cross-body. In one embodiment, the binding agent is a bispecific antibody obtained by controlled Fab arm exchange (eg, as described in WO2011131746 (Genmab)).

[0777] Some examples of different classes of binding agents include, but are not limited to (i) IgG-like molecules with complementary CH3 domains to force heterodimerization; (ii) recombinant IgG-like dual-targeting molecules, wherein each side of the molecule comprises a Fab fragment or a portion of a Fab fragment of at least two different antibodies; (iii) IgG fusion molecules, wherein a full-length IgG antibody is fused to an additional Fab fragment or a portion of a Fab fragment; (iv) Fc fusion molecules, wherein a single-chain Fv molecule or a stabilized diabody is fused to a heavy chain constant domain, an Fc region, or a portion thereof; (v) Fab fusion molecules, wherein different Fab fragments are fused together, fused to a heavy chain constant domain, an Fc region, or a portion thereof; and (vi) ScFv and diabody-based antibodies and heavy chain antibodies (e.g., domain antibodies, nanobodies), wherein different single-chain Fv molecules or different diabodies or different heavy chain antibodies (e.g., domain antibodies, nanobodies) are fused to each other or to another protein or carrier molecule fused to a heavy chain constant domain, an Fc region, or a portion thereof.

[0778] Some examples of IgG-like molecules with complementary CH3 domain molecules include, but are not limited to, Triomab / Quadroma molecules (Trion Pharma / Fresenius Biotech; Roche, WO2011069104), so-called Knob-into-Hole molecules (Genentech, WO9850431), CrossMAb (Roche, WO2011117329), and electrostatic matching molecules (Amgen, EP1870459 and WO2009089004; Chugai, US201000155133; Oncomed, WO2010129304), LUZ-Y molecules (Genentech, Wranik et al. J. Biol. Chem. 2012, 287(52):43331-9, doi:10.1074 / jbc.M112.397869. Epub 2012 Nov 1), DIG body and PIG body molecules (Pharmabcine, WO2010134666, WO2014081202), Strand Exchange Engineered Domain Body (SEEDbody) molecules (EMD Serono, WO2007110205), Biclonics molecules (Merus, WO2013157953), FcΔAdp molecules (Regeneron, WO201015792), bispecific IgG1 and IgG2 molecules (Pfizer / Rinat, WO11143545), Azymetric scaffold molecules (Zymeworks / Merck, WO2012058768) molecules, mAb-Fv molecules (Xencor, WO2011028952), bivalent bispecific antibodies (WO2009080254) and molecule (Genmab, WO2011131746).

[0779] Some examples of recombinant IgG-like dual targeting molecules include, but are not limited to, dual targeting (DT)-Ig molecules (WO2009058383), two-in-one antibodies (Genentech; Bostrom, et al. 2009. Science 323, 1610-1614.), cross-linked Mab (Karmanos Cancer Center), mAb2 (F-Star, WO2008003116), Zybody molecules (Zyngenia; LaFleur et al. MAbs. 2013 Mar-Apr; 5(2): 208-18), methods using common light chains (Crucell / Merus, US7,262,028), κλ bodies (NovImmune, WO2012023053) and CovX bodies (CovX / Pfizer; Doppalapudi, VR, et al. 2007. Bioorg. Med. Chem. Lett. 17, 501-506.).

[0780] Some examples of IgG fusion molecules include, but are not limited to, dual variable domain (DVD)-Ig molecules (Abbott, US7,612,181), dual domain bihead antibodies (Unilever; Sanofi Aventis, WO20100226923), IgG-like bispecific molecules (ImClone / Eli Lilly, Lewis et al. Nat Biotechnol. 2014 Feb; 32(2): 191-8), Ts2Ab (MedImmune / AZ; Dimasi et al. J Mol Biol. 2009 Oct 30; 393(3): 672-92) and BsAb molecules (Zymogenetics, WO2010111625), HERCULES molecules (Biogen Idec, US007951918), scFv fusion molecules (Novartis), scFv fusion molecules (Changzhou Adam Biotech Inc, CN 102250246) and TvAb molecules (Roche, WO2012025525, WO2012025530).

[0781] Some examples of Fc fusion molecules include, but are not limited to, ScFv / Fc fusions (Pearce et al., Biochem Mol Biol Int. 1997 Sep; 42(6): 1179-88), SCORPION molecules (Emergent BioSolutions / Trubion, Blankenship JW, et al. AACR 100th Annual meeting 2009 (Abstract #5465); Zymogenetics / BMS, WO2010111625), Dual Affinity Retargeting Technology (Fc-DART) molecules (MacroGenics, WO2008157379, WO2010080538), and bi-(ScFv)2-Fab molecules (National Research Center for Antibody Medicine-China).

[0782] Some examples of Fab fusion bispecific antibodies include, but are not limited to, F(ab)2 molecules (Medarex / AMGEN; Deo et al J Immunol. 1998 Feb 15; 160(4): 1677-86.), Dual-Action or Bis-Fab molecules (Genentech, Bostrom, et al 2009. Science 323, 1610-1614.), Dock-and-Lock (DNL) molecules (ImmunoMedics, WO2003074569, WO2005004809), bivalent bispecific molecules (Biotecnol, Schoonjans, J Immunol. 2000 Dec 15; 165(12): 7050-7.) and Fab-Fv molecules (UCB-Celltech, WO 2009040562 A1).

[0783] Some examples of ScFv-based, diabody-based and domain antibodies include, but are not limited to, bispecific T cell engager (BiTE) molecules (Micromet, WO2005061547), tandem diabody molecules (TandAb) (Affimed) Le Gall et al., Protein Eng Des Sel. 2004 Apr; 17(4): 357-66.), dual affinity retargeting technology (DART) molecules (MacroGenics, WO2008157379, WO2010080538), single chain diabody molecules (Lawrence, FEBS Lett. 1998 Apr 3; 425(3): 479-84), TCR-like antibodies (AIT, Receptor Logics), human serum albumin ScFv fusions (Merrimack, WO2010059315) and COMBODY molecules (Epigen Biotech, Zhu et al., WO2010059315). al.Immunol Cell Biol.2010Aug;88(6):667-75.), dual-targeting nanobodies (Ablynx, Hmila et al., FASEB J.2010) and dual-targeting heavy chain domain-only antibodies.

[0784] In one aspect, the bispecific antibody of the present disclosure comprises a first Fc sequence and a second Fc sequence, wherein the first Fc sequence comprises a first CH3 region, and the second Fc sequence comprises a second CH3 region, wherein the sequences of the first CH3 region and the second CH3 region are different and the heterodimer interaction between the first CH3 region and the second CH3 region is made stronger than the homodimer interaction of each of the first CH3 region and the second CH3 region. More detailed information about these interactions and how they can be achieved is provided in WO2011131746 and WO2013060867 (Genmab), which are incorporated by reference herein.

[0785] As further described herein, a specific method based on a homodimeric starting EpCAM antibody and a homodimeric starting CD137 antibody containing only a few conservative asymmetric mutations in the CH3 region can be used to obtain stable bispecific EpCAMxCD137 antibodies with high yield. Asymmetric mutations mean that the sequences of the first CH3 region and the second CH3 region contain amino acid substitutions at different positions.

[0786] In one embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises a first CH3 region having an amino acid substitution at a position selected from the group consisting of: 366, 368, 370, 399, 405, 407 and 409 in a human IgG1 heavy chain, and a second CH3 region having an amino acid substitution at a position selected from the group consisting of: 366, 368, 370, 399, 405, 407 and 409 in a human IgG1 heavy chain, and wherein the first CH3 region and the second CH3 region are not substituted at the same position.

[0787] In one embodiment, the bispecific antibody defined in any embodiment disclosed herein comprises the sequence of the first CH3 region and the second CH3 region, which contains an asymmetric mutation, i.e., a mutation at different positions in the two CH3 regions, such as a mutation at position 405 in one CH3 region and a mutation at position 409 in the other CH3 region. In one embodiment, the mutation at position 405 is F405L. In one embodiment, the mutation at position 409 is K409R.

[0788] In one embodiment, the bispecific antibody comprises a first heavy chain and a second heavy chain, wherein the first heavy chain and the second heavy chain each comprise at least a hinge region, a CH2 region, and a CH3 region, wherein (i) in the first heavy chain, the amino acid at the position corresponding to F405 in the human IgG1 heavy chain is L, and in the second heavy chain, the amino acid at the position corresponding to K409 in the human IgG1 heavy chain is R, or (ii) in the first heavy chain, the amino acid at the position corresponding to K409 in the human IgG1 heavy chain is R, and in the second heavy chain, the amino acid at the position corresponding to F405 in the human IgG1 heavy chain is L.

[0789] Conventional methods such as hybrid hybridoma and chemical conjugation methods (Marvin and Zhu (2005) Acta Pharmacol Sin 26: 649) can be used to prepare the bispecific antibodies described herein. The co-expression of two antibodies consisting of different heavy and light chains in a host cell results in a mixture of possible antibody products in addition to the desired bispecific antibody, which can then be separated by, for example, affinity chromatography or a similar method.

[0790] It is also possible to use strategies that are conducive to the formation of functional bispecific products after co-expression of different antibody constructs, such as the method described by Lindhofer et al. (1995 J Immunol 155: 219). Due to the preferred species-restricted heavy / light chain pairing, the fusion of rat and mouse hybridomas that produce different antibodies leads to a limited number of heterodimeric proteins. Another strategy to promote heterodimers to form in preference to homodimers is the "knob-in-hole" strategy, in which a protuberance is introduced on the first heavy chain polypeptide and a corresponding cavity is introduced in the second heavy chain polypeptide so that the protuberance can be located in the cavity at the interface of the two heavy chains to promote the formation of heterodimers and hinder the formation of homodimers. "Protuberance" is constructed by replacing the small amino acid side chains from the interface of the first polypeptide with larger side chains. Compensatory "cavities" of the same or similar size to the protuberance are produced in the interface of the second polypeptide by replacing large amino acid side chains with smaller amino acid side chains (U.S. Patent No. 5,731,168). EP1870459 (Chugai) and WO2009089004 (Amgen) describe other strategies that favor heterodimer formation after co-expression of different antibody domains in host cells. In these methods, one or more residues constituting the CH3-CH3 interface in the two CH3 domains are replaced by charged amino acids, making the formation of homodimers electrostatically unfavorable, while heterodimers are electrostatically favorable. WO2007110205 (Merck) describes another strategy in which the differences between IgA and IgG CH3 domains are utilized to promote heterodimerization.

[0791] Another in vitro method for producing bispecific antibodies has been described in WO2008119353 (Genmab), in which the bispecific antibodies are formed by "Fab arm" or "half molecule" exchange (exchanging heavy chain and attached light chain) between two monospecific IgG4 or IgG4-like antibodies after incubation under reducing conditions. The resulting product is a bispecific antibody with two Fab arms that may contain different sequences.

[0792] Preferred methods for preparing the bispecific EpCAMxCD137 antibodies of the present disclosure include the methods described in WO2011131746 and WO2013060867 (Genmab), comprising the following steps:

[0793] a) providing a primary antibody comprising an Fc region, wherein the Fc region comprises a first CH3 region;

[0794] b) providing a secondary antibody comprising a second Fc region, said Fc region comprising a second CH3 region, wherein the primary antibody is an EpCAM antibody and the secondary antibody is a CD137 antibody, or vice versa;

[0795] wherein the sequences of the first CH3 region and the second CH3 region are different and such that the heterodimer interaction between the first CH3 region and the second CH3 region is stronger than the homodimer interaction between the first CH3 region and the second CH3 region;

[0796] c) incubating the primary antibody with the secondary antibody under reducing conditions; and

[0797] d) obtaining the bispecific EpCAMxCD137 antibody.

[0798] Similarly, there is provided a method for producing an antibody according to the present disclosure comprising the following steps:

[0799] a) culturing a host cell producing a primary antibody, and purifying the primary antibody from the culture, wherein the primary antibody comprises an antigen binding region capable of binding to human EpCAM as defined herein;

[0800] b) culturing host cells producing a second antibody, and purifying the second antibody from the culture, wherein the second antibody comprises an antigen binding region capable of binding to human CD137 as defined herein;

[0801] c) incubating the primary antibody with the secondary antibody under reducing conditions sufficient to cause the cysteine ​​in the hinge region to undergo dis...

Claims

1. A binding agent comprising a first antigen binding region that binds to EpCAM and a second antigen binding region that binds to CD137.

2. The binding agent of claim 1, wherein the EpCAM is human EpCAM.

3. The binding agent of claim 1 or 2, wherein the CD137 is human CD137. 4 . The binding agent of claim 1 , wherein the first antigen binding region that binds to EpCAM binds to EpCAM expressed on tumor cells.

5. The binding agent of any one of claims 1 to 4, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR3 sequence comprising the sequence shown in SEQ ID NO:

4.

6. The binding agent of any one of claims 1 to 5, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR2 sequence comprising the sequence shown in SEQ ID NO:

3.

7. The binding agent of any one of claims 1 to 6, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising a HCDR1 sequence comprising the sequence shown in SEQ ID NO:

2.

8. The binding agent of any one of claims 1 to 7, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3, and 4, respectively.

9. The binding agent of any one of claims 1 to 8, wherein the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR3 sequence, wherein the LCDR3 sequence comprises the sequence shown in SEQ ID NO:

8.

10. The binding agent of any one of claims 1 to 9, wherein the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR2 sequence, wherein the LCDR2 sequence comprises the sequence shown in SEQ ID NO:

7.

11. The binding agent of any one of claims 1 to 10, wherein the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising a LCDR1 sequence, wherein the LCDR1 sequence comprises the sequence shown in SEQ ID NO:

6.

12. The binding agent of any one of claims 1 to 11, wherein the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences, wherein the LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7, and 8, respectively.

13. The binding agent of any one of claims 1 to 12, wherein the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively.

14. The binding agent of any one of claims 1 to 13, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH), which comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:

1.

15. The binding agent of any one of claims 1 to 14, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO:

1.

16. The binding agent of any one of claims 1 to 15, wherein the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL), wherein the light chain variable region (VL) comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:

5.

17. The binding agent of any one of claims 1 to 16, wherein the first antigen binding region that binds to EpCAM comprises a light chain variable region (VL) comprising the sequence shown in SEQ ID NO:

5.

18. The binding agent of any one of claims 1 to 17, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the sequence shown in SEQ ID NO: 1, and the VL comprises the sequence shown in SEQ ID NO:

5.

19. The binding agent of any one of claims 1 to 18, wherein the first antigen binding region that binds to EpCAM comprises a heavy chain variable region and a light chain variable region of an antibody that competes for EpCAM binding with an antibody comprising a heavy chain variable region (VH) and / or a light chain variable region (VL) as shown in any one of claims 5 to 18 and / or has the EpCAM specificity of the antibody.

20. The binding agent of any one of claims 1 to 19, wherein the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a HCDR3 sequence comprising the sequence shown in SEQ ID NO:

14.

21. The binding agent of any one of claims 1 to 20, wherein the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a HCDR2 sequence comprising the sequence shown in SEQ ID NO:

13.

22. The binding agent of any one of claims 1 to 21, wherein the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a HCDR1 sequence comprising the sequence shown in SEQ ID NO:

12.

23. The binding agent of any one of claims 1 to 22, wherein the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1, HCDR2, and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13, and 14, respectively.

24. The binding agent of any one of claims 1 to 23, wherein the second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising a LCDR3 sequence, wherein the LCDR3 sequence comprises the sequence shown in SEQ ID NO:

18.

25. The binding agent of any one of claims 1 to 24, wherein the second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising a LCDR2 sequence comprising the sequence shown in SEQ ID NO:

17.

26. The binding agent of any one of claims 1 to 25, wherein the second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising a LCDR1 sequence comprising the sequence shown in SEQ ID NO:

16.

27. The binding agent of any one of claims 1 to 26, wherein the second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences, wherein the LCDR1, LCDR2, and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17, and 18, respectively.

28. The binding agent of any one of claims 1 to 27, wherein the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

29. The binding agent of any one of claims 1 to 28, wherein the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:

11.

30. The binding agent of any one of claims 1 to 29, wherein the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) comprising the sequence shown in SEQ ID NO:

11.

31. The binding agent of any one of claims 1 to 30, wherein the second antigen binding region that binds to CD137 comprises a light chain variable region (VL), the light chain variable region (VL) comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:

15.

32. The binding agent of any one of claims 1 to 31, wherein the second antigen binding region that binds to CD137 comprises a light chain variable region (VL) comprising the sequence shown in SEQ ID NO:

15.

33. The binding agent of any one of claims 1 to 32, wherein the second antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the sequence shown in SEQ ID NO: 11, and the VL comprises the sequence shown in SEQ ID NO:

15.

34. The binding agent of any one of claims 1 to 33, wherein the second antigen-binding region that binds to CD137 comprises a heavy chain variable region and a light chain variable region of an antibody that competes for CD137 binding with an antibody comprising a heavy chain variable region and / or a light chain variable region as shown in any one of claims 20 to 33 and / or has the CD137 specificity of the antibody.

35. The binding agent of any one of claims 1 to 34, wherein: a) the first antigen-binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and b) the second antigen-binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

36. The binding agent of any one of claims 1 to 35, wherein the binding agent is in the form of a full-length antibody or an antibody fragment.

37. The binding agent of any one of claims 1 to 36, wherein the binding agent comprises an Fc region.

38. The binding agent of any one of claims 1 to 37, wherein the binding agent is a multispecific binding agent, such as a bispecific binding agent.

39. The binding agent of any one of claims 1 to 38, wherein the binding agent is a bispecific, bivalent binding agent.

40. The binding agent of any one of claims 1 to 39, which does not comprise an antigen binding region that binds to EpCAM other than the first antigen binding region that binds to EpCAM, and does not comprise an antigen binding region that binds to CD137 other than the second antigen binding region that binds to CD137.

41. The binding agent of any one of claims 1 to 40, wherein the binding agent is an antibody comprising a first binding arm comprising the first antigen binding region that binds to EpCAM and a second binding arm comprising the second antigen binding region that binds to CD137, wherein: The first binding arm comprises i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL); and the second binding arm comprises iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL).

42. The binding agent of claim 41, wherein: The first VH comprises a first HCDR1, HCDR2 and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2 and LCDR3 sequence, wherein the first HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the first LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and The second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

43. The binding agent of claim 41 or 42, wherein: The first VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 1, and the first VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 5; and The second VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:11, and the second VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:

15.

44. The binding agent of any one of claims 41 to 43, wherein: The first VH comprises the amino acid sequence shown in SEQ ID NO: 1, and the first VL comprises the amino acid sequence shown in SEQ ID NO: 5; and The second VH comprises the amino acid sequence shown in SEQ ID NO:11, and the second VL comprises the amino acid sequence shown in SEQ ID NO:

15.

45. The binding agent of any one of claims 41 to 44, wherein the first and second heavy chain constant regions (CH) each comprise one or more of a constant heavy chain 1 (CH1) region, a hinge region, a constant heavy chain 2 (CH2) region, and a constant heavy chain 3 (CH3) region, preferably at least a hinge region, a CH2 region, and a CH3 region.

46. ​​The binding agent of any one of claims 41 to 45, wherein the first and second heavy chain constant regions (CH) each comprise a CH3 region, and wherein the two CH3 regions comprise an asymmetric mutation.

47. The binding agent of any one of claims 41 to 46, wherein (i) in the first heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) in the first heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

48. The binding agent of any one of claims 41 to 47, wherein the binding agent induces Fc-mediated effector function to a lesser extent than another antibody comprising the same first and second antigen binding regions and two heavy chain constant regions (CH) containing human IgG1 hinge, CH2 and CH3 regions.

49. The binding agent of any one of claims 41 to 48, wherein the first and second heavy chain constant regions (CH) are modified such that the antibody induces Fc-mediated effector function to a lesser extent than an antibody that is identical except for comprising unmodified first and second heavy chain constant regions (CH).

50. The binding agent of any one of claims 41 to 49, wherein in at least one of the first and second heavy chain constant regions (CH), one or more amino acids in the positions corresponding to positions L234, L235, D265, N297, P331 and G236 in a human IgG1 heavy chain according to EU numbering are not L, L, D, N, P and G, respectively.

51. The binding agent of claim 50, wherein in the first and second heavy chains, the positions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively.

52. The binding agent of claim 50 or 51, wherein in the first and / or second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and / or in the first and / or second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

53. The binding agent of any one of claims 50 to 52, wherein: (i) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively; (ii) in both the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively; or (iii) in one of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the other of the first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

54. The binding agent of any one of claims 50 to 53, wherein the positions in both the first and second heavy chain constant regions corresponding to positions L234 and L235 in a human IgG1 heavy chain according to EU numbering are F and E, respectively, and wherein (i) the position in the first heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L, and the position in the second heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R, or (ii) the position in the first heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R, and the position in the second heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L.

55. The binding agent of any one of claims 50 to 54, wherein in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein (i) the position in the first heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L, and the position in the second heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R, or (ii) the position in the first heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R, and the position in the second heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L.

56. The binding agent of any one of claims 50 to 55, wherein in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein the position in the first heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L, and the position in the second heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R.

57. The binding agent of any one of claims 41 to 56, wherein: a) the constant region of the first heavy chain comprises the amino acid sequence shown in SEQ ID NO: 54; and b) the constant region of the second heavy chain comprises the amino acid sequence shown in SEQ ID NO:

52.

58. The binding agent of any one of claims 1 to 57, wherein the binding agent is an antibody comprising a first binding arm comprising the first antigen binding region that binds to EpCAM and a second binding arm comprising the second antigen binding region that binds to CD137, wherein: The first binding arm comprises i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL), wherein the first VH comprises a first HCDR1, HCDR2 and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2 and LCDR3 sequence, wherein the first HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the first LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and the second binding arm comprises iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL), wherein the second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively; wherein in the first CH, positions L234, L235 and G236 in the human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and in the second CH, positions L234, L235 and D265 in the human IgG1 heavy chain according to EU numbering are F, E and A; and wherein in the first CH, the amino acid in the position corresponding to F405 in human IgG1 heavy chain according to EU numbering is L, and in the second CH, the amino acid in the position corresponding to K409 in human IgG1 heavy chain according to EU numbering is R.

59. The binding agent of any one of claims 1 to 58, comprising: i) a first heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:9, ii) a first light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 10, iii) a second heavy chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 19; and iv) a second light chain comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:

20.

60. The binding agent of any one of claims 1 to 59, comprising: i) a first heavy chain, the first heavy chain comprising the amino acid sequence shown in SEQ ID NO: 9, ii) a first light chain, the first light chain comprising the amino acid sequence shown in SEQ ID NO: 10, iii) a second heavy chain comprising the amino acid sequence shown in SEQ ID NO: 19; and iv) a second light chain, wherein the second light chain comprises the amino acid sequence shown in SEQ ID NO:

20.

61. A binding agent comprising a first binding arm and a second binding arm, wherein the first binding arm comprises a first antigen binding region and a first heavy chain constant region comprising a constant heavy chain 2 (CH2) region, and the second binding arm comprises a second antigen binding region and a second heavy chain constant region comprising a constant heavy chain 2 (CH2) region, wherein at least one of the first and second antigen binding regions binds to EpCAM, and wherein in at least one of said first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

62. The binding agent of claim 61, wherein in the first and / or second heavy chain constant region, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

63. The binding agent of claim 61 or 62, wherein in both the first and / or second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

64. The binding agent of claim 61 or 62, wherein in one of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the other of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively.

65. The binding agent of any one of claims 61 to 64, wherein both the first and second antigen binding regions bind to EpCAM.

66. The binding agent of any one of claims 61 to 64, wherein one of the first and second antigen binding regions binds to EpCAM and the other of the first and second antigen binding regions binds to an antigen other than EpCAM.

67. The binding agent of any one of claims 61 to 64 and 66, wherein one of the first and second antigen binding regions binds to EpCAM and the other of the first and second antigen binding regions binds to CD137.

68. A binding agent comprising a first binding arm and a second binding arm, wherein the first binding arm comprises a first antigen binding region and a first heavy chain constant region comprising a constant heavy chain 2 (CH2) region, and the second binding arm comprises a second antigen binding region and a second heavy chain constant region comprising a constant heavy chain 2 (CH2) region, wherein at least one of the first and second antigen binding regions binds to CD137, and wherein in at least one of said first and second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

69. The binding agent of claim 68, wherein in the first and / or second heavy chain constant region, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

70. The binding agent of claim 68 or 69, wherein in both the first and / or second heavy chain constant regions, the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively.

71. The binding agent of claim 68 or 69, wherein in one of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and G236 in a human IgG1 heavy chain according to EU numbering are F, E, and R, respectively, and in the other of the first or second heavy chain constant regions, the positions corresponding to positions L234, L235, and D265 in a human IgG1 heavy chain according to EU numbering are F, E, and A, respectively.

72. The binding agent of any one of claims 68 to 71, wherein both the first and second antigen binding regions bind to CD137.

73. The binding agent of any one of claims 68 to 71, wherein one of the first and second antigen binding regions binds to CD137 and the other of the first and second antigen binding regions binds to an antigen other than CD137.

74. The binding agent of any one of claims 68 to 71 and 73, wherein one of the first and second antigen binding regions binds to CD137 and the other of the first and second antigen binding regions binds to EpCAM.

75. The binding agent of any one of claims 61 to 67 and 74, wherein the EpCAM is human EpCAM.

76. The binding agent of any one of claims 61 to 67, 74 and 75, wherein the antigen binding region that binds to EpCAM binds to EpCAM expressed on tumor cells.

77. The binding agent of any one of claims 61 to 67 and 74 to 76, wherein the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively.

78. The binding agent of any one of claims 61 to 67 and 74 to 77, wherein the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO: 1, and the VL comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:

5.

79. The binding agent of any one of claims 61 to 67 and 74 to 78, wherein the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the sequence shown in SEQ ID NO: 1, and the VL comprises the sequence shown in SEQ ID NO:

5.

80. The binding agent of any one of claims 67 to 79, wherein the CD137 is human CD137.

81. The binding agent of any one of claims 67 to 80, wherein the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprising HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprising LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

82. The binding agent of any one of claims 67 to 81, wherein the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO: 11, and the VL comprises a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% or 100% identical to the sequence shown in SEQ ID NO:

15.

83. The binding agent of any one of claims 67 to 82, wherein the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises the sequence shown in SEQ ID NO: 11, and the VL comprises the sequence shown in SEQ ID NO:

15.

84. The binding agent of any one of claims 61 to 64, 66 to 71, and 73 to 83, comprising an antigen binding region that binds to EpCAM and an antigen binding region that binds to CD137, wherein: a) the antigen binding region that binds to EpCAM comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and b) the antigen binding region that binds to CD137 comprises a heavy chain variable region (VH) and a light chain variable region (VL), the heavy chain variable region (VH) comprises HCDR1, HCDR2 and HCDR3 sequences, the light chain variable region (VL) comprises LCDR1, LCDR2 and LCDR3 sequences, wherein the HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

85. The binding agent of any one of claims 61 to 84, wherein the binding agent is a bivalent binding agent.

86. The binding agent of any one of claims 61 to 85, wherein the binding agent comprises an Fc region.

87. The binding agent of any one of claims 61 to 86, wherein the binding agent is in the form of an antibody, such as in the form of a full-length antibody.

88. The binding agent of any one of claims 61 to 64, 66 to 71, and 73 to 87, comprising a first binding arm comprising an antigen binding region that binds to EpCAM and a second binding arm comprising an antigen binding region that binds to CD137, wherein: The first binding arm comprises i) a polypeptide comprising a first heavy chain variable region (VH) and a first heavy chain constant region (CH), and ii) a polypeptide comprising a first light chain variable region (VL) and a first light chain constant region (CL); and the second binding arm comprises iii) a polypeptide comprising a second heavy chain variable region (VH) and a second heavy chain constant region (CH), and iv) a polypeptide comprising a second light chain variable region (VL) and a second light chain constant region (CL).

89. The binding agent of claim 88, wherein: The first VH comprises a first HCDR1, HCDR2 and HCDR3 sequence, and the first VL comprises a first LCDR1, LCDR2 and LCDR3 sequence, wherein the first HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 2, 3 and 4, respectively, and the first LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 6, 7 and 8, respectively; and The second VH comprises a second HCDR1, HCDR2 and HCDR3 sequence, and the second VL comprises a second LCDR1, LCDR2 and LCDR3 sequence, wherein the second HCDR1, HCDR2 and HCDR3 sequences comprise the sequences shown in SEQ ID NOs: 12, 13 and 14, respectively, and the second LCDR1, LCDR2 and LCDR3 sequences comprise the sequences shown in SEQ ID NOs: 16, 17 and 18, respectively.

90. The binding agent of claim 88 or 89, wherein: The first VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 1, and the first VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% identical to the amino acid sequence shown in SEQ ID NO: 5; and The second VH comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:11, and the second VL comprises an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97% or at least 99% identical to the amino acid sequence shown in SEQ ID NO:

15.

91. The binding agent of any one of claims 88 to 90, wherein: The first VH comprises the amino acid sequence shown in SEQ ID NO: 1, and the first VL comprises the amino acid sequence shown in SEQ ID NO: 5; and The second VH comprises the amino acid sequence shown in SEQ ID NO:11, and the second VL comprises the amino acid sequence shown in SEQ ID NO:

15.

92. The binding agent of any one of claims 61 to 91, wherein the first and second heavy chain constant regions (CH) each comprise a CH3 region, and wherein the two CH3 regions comprise an asymmetric mutation.

93. The binding agent of claim 92, wherein (i) in the first heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, or (ii) in the first heavy chain constant region (CH), the amino acid in the position corresponding to K409 in the human IgG1 heavy chain according to EU numbering is R, and in the second heavy chain constant region (CH), the amino acid in the position corresponding to F405 in the human IgG1 heavy chain according to EU numbering is L.

94. The binding agent of claim 92 or 93, wherein in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein (i) the position in the first heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L, and the position in the second heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R, or (ii) the position in the first heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R, and the position in the second heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L.

95. The binding agent of any one of claims 92 to 94, wherein in the second heavy chain constant region (HC), the positions corresponding to positions L234, L235 and D265 in a human IgG1 heavy chain according to EU numbering are F, E and A, respectively, and in the first heavy chain constant region (HC), the positions corresponding to positions L234, L235 and G236 in a human IgG1 heavy chain according to EU numbering are F, E and R, respectively, and wherein the position in the first heavy chain constant region corresponding to F405 in a human IgG1 heavy chain according to EU numbering is L, and the position in the second heavy chain constant region corresponding to K409 in a human IgG1 heavy chain according to EU numbering is R.

96. A polynucleotide or set of polynucleotides encoding the binding agent of any one of claims 1 to 95.

97. A pharmaceutical composition comprising the binding agent of any one of claims 1 to 95 or the polynucleotide of claim 96.

98. A method for treating a subject, comprising administering to the subject the binding agent of any one of claims 1 to 95, the polynucleotide of claim 96, or the pharmaceutical composition of claim 97.

99. The method of claim 98, which is a method for treating or preventing cancer in a subject.

100. The method of claim 99, wherein the subject is a human.

101. The binding agent of any one of claims 1 to 95, the polynucleotide of claim 96, or the pharmaceutical composition of claim 97 for pharmaceutical use, such as as a medicament.

102. The binding agent, polynucleotide or pharmaceutical composition of claim 101 for use in the therapeutic or prophylactic treatment of a disease or disorder.

103. The binding agent, polynucleotide or pharmaceutical composition of claim 102, wherein the disease or disorder is cancer.

104. The binding agent of any one of claims 1 to 95, the polynucleotide of claim 96, or the pharmaceutical composition of claim 97, for use in treating or preventing cancer in a subject.

105. The binding agent, polynucleotide or pharmaceutical composition of claim 104, wherein the subject is a human.